Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness
Barbara H. Stokes, Satish K. Dhingra, Kelly Rubiano, Sachel Mok, Judith Straimer, Nina F. Gnadig, Ioanna Deni, Kyra A. Schindler, Jade R. Bath, Kurt E. Ward, et al.

To cite this version:
Barbara H. Stokes, Satish K. Dhingra, Kelly Rubiano, Sachel Mok, Judith Straimer, et al.. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. eLife, 2021, 10, pp.e66277. 10.7554/eLife.66277. pasteur-03291682

HAL Id: pasteur-03291682
https://riip.hal.science/pasteur-03291682
Submitted on 19 Jul 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

Barbara H. Stokes¹, Satish K. Dhingra¹, Kelly Rubiano¹, Sachel Mok¹, Judith Straimer¹, Nina F. Gnädig¹, Ioanna Deni¹, Kyra A. Schindler¹, Jade R. Bath¹, Kurt E. Ward¹,², Josefine Striepen¹, Tomas Yeo¹, Leila S. Ross¹, Eric Legrand³, Frédéric Ariey⁴, Clark H. Cunningham¹,⁵, Issa M. Souleymane⁶, Adama Gansané⁶, Romaric Nzoumbou-Boko⁸, Claudette Ndayikunda⁹, Abdunoor M. Kabanywanyi¹⁰, Aline Uwimana¹¹, Samuel J. Smith¹², Olimatou Kolley¹³, Mathieu Ndounga¹⁴, Marian Warsame¹⁵, Rithea Leang¹⁶, François Nosten¹⁷,¹⁸, Timothy J.C. Anderson¹⁹, Philip J. Rosenthal²⁰, Didier Ménard³, David A. Fidock¹,²¹‡

¹Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA; ²Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand; ³Malaria Genetics and Resistance Unit, Institut Pasteur, INSERM U1201, CNRS ERL9195, Paris, France; ⁴Institut Cochin INSERM U1016, Université Paris Descartes, Paris, France; ⁵Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ⁶Programme National de Lutte Contre le Paludisme au Tchad, Ndjamena, Chad; ⁷Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso; ⁸Laboratory of Parasitology, Institute Pasteur of Bangui, Bangui, Central African Republic; ⁹University Teaching Hospital of Kamenge, Bujumbura, Burundi; ¹⁰Ifakara Health Institute, Dar es Salaam, Tanzania; ¹¹Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre, Kigali, Rwanda; ¹²National Malaria Control Programme, Sierra Leone; ¹³National Malaria Control Program, Banjul, The Gambia; ¹⁴Programme National de Lutte Contre le Paludisme, Brazzaville, République du Congo; ¹⁵School of Public Health and Community Medicine, University of Gothenburg, Sweden; ¹⁶National Center for Parasitology, Entomology & Malaria Control, Phnom Penh, Cambodia; ¹⁷Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; ¹⁸Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; ¹⁹Texas Biomedical Research Institute, San Antonio, TX, USA; ²⁰Department of Medicine, University of California, San Francisco, CA, USA; ²¹Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
†Corresponding author. Email: df2260@cumc.columbia.edu
Abstract

The emergence of mutant K13-mediated artemisinin (ART) resistance in *Plasmodium falciparum* malaria parasites has led to widespread treatment failure across Southeast Asia. In Africa, K13-propeller genotyping confirms the emergence of the R561H mutation in Rwanda and highlights the continuing dominance of wild-type K13 elsewhere. Using gene editing, we show that R561H, along with C580Y and M579I, confer elevated *in vitro* ART resistance in some African strains, contrasting with minimal changes in ART susceptibility in others. C580Y and M579I cause substantial fitness costs, which may slow their dissemination in high-transmission settings, in contrast with R561H that in African 3D7 parasites is fitness neutral. In Cambodia, K13 genotyping highlights the increasing spatio-temporal dominance of C580Y. Editing multiple K13 mutations into a panel of Southeast Asian strains reveals that only the R561H variant yields ART resistance comparable to C580Y. In Asian Dd2 parasites C580Y shows no fitness cost, in contrast with most other K13 mutations tested, including R561H. Editing point mutations in *ferredoxin* or *mdr2*, earlier associated with resistance, has no impact on ART susceptibility or parasite fitness. These data underline the complex interplay between K13 mutations, parasite survival, growth and genetic background in contributing to the spread of ART resistance.
Introduction

Despite recent advances in chemotherapeutics, diagnostics and vector control measures, malaria continues to exert a significant impact on human health (Hanboonkunupakarn and White, 2020). In 2019, cases were estimated at 229 million, resulting in 409,000 fatal outcomes, primarily in Sub-Saharan Africa as a result of *Plasmodium falciparum* infection (WHO, 2020). This situation is predicted to worsen as a result of the ongoing SARS-CoV-2 pandemic that has compromised malaria treatment and prevention measures (Sherrard-Smith et al., 2020). Absent an effective vaccine, malaria control and elimination strategies are critically reliant on the continued clinical efficacy of first-line artemisinin-based combination therapies (ACTs) (White et al., 2014).

These ACTs pair fast-acting artemisinin (ART) derivatives with partner drugs such as lumefantrine, amodiaquine, mefloquine or piperaquine (PPQ). ART derivatives can reduce the biomass of drug-sensitive parasites by up to 10,000-fold within 48 h (the duration of one intra-erythrocytic developmental cycle); however, these derivatives are rapidly metabolized *in vivo*. Longer-lasting albeit slower-acting partner drugs are co-administered to reduce the selective pressure for ART resistance and to clear residual parasitemias (Eastman and Fidock, 2009).

*P. falciparum* resistance to ART derivatives has now swept across Southeast (SE) Asia, having first emerged a decade ago in western Cambodia (Dondorp et al., 2009; Noedl et al., 2009; Ariey et al., 2014; Imwong et al., 2020). Clinically, ART resistance manifests as delayed clearance of circulating asexual blood stage parasites following treatment with an ACT but does not result in treatment failure as long as the partner drug remains effective. The accepted threshold for resistance is a parasite clearance half-life (the time required for the peripheral blood parasite density to decrease by 50%) of >5.5 h. Sensitive parasites are typically cleared in <2-3 h (WHO, 2019). Resistance can also be evidenced as parasite-positive blood smears on day three post initiation of treatment. *In vitro*, ART resistance manifests as an increase in survival in tightly synchronized ring-stage parasites (0-3 h post invasion) exposed to a 6 h pulse of 700 nM dihydroartemisinin (DHA, the active metabolite of all ARTs used clinically) in the ring-stage survival assay (RSA) (Witkowski et al., 2013; Ariey et al., 2014).

Recently, ART-resistant strains have also acquired resistance to PPQ, which is widely used in SE Asia as a partner drug in combination with DHA (Wicht et al., 2020). Failure rates following DHA-PPQ treatment now exceed 50% in parts of Cambodia, Thailand and Vietnam (van der Pluijm et al., 2019).
In vitro selections, supported by clinical epidemiological data, have demonstrated that ART resistance is primarily determined by mutations in the beta-propeller domain of the *P. falciparum* Kelch protein K13, also known as Kelch13 (Ariey et al., 2014; Ashley et al., 2014; MalariaGEN, 2016; Menard et al., 2016; Siddiqui et al., 2020). Recent evidence suggests that these mutations result in reduced endocytosis of host-derived hemoglobin and thereby decrease the release of Fe$^{2+}$-heme that serves to activate ART, thus reducing its potency (Yang et al., 2019; Birnbaum et al., 2020). Mutations in other genes including ferredoxin (fd) and multidrug resistance protein 2 (mdr2) have also been associated with ART resistance in K13 mutant parasites, leading to the suggestion that they either contribute to a multigenic basis of resistance or fitness or serve as genetic markers of founder populations (Miotto et al., 2015).

In SE Asia, the most prevalent K13 mutation is C580Y, which associates with delayed clearance in vivo (Ariey et al., 2014; Ashley et al., 2014; MalariaGEN, 2016; Menard et al., 2016; Imwong et al., 2017). This mutation also mediates ART resistance in vitro, as demonstrated by RSAs performed on gene-edited parasites (Ghorbal et al., 2014; Straimer et al., 2015; Straimer et al., 2017; Mathieu et al., 2020; Uwimana et al., 2020). Other studies have documented the emergence of nearly 200 other K13 mutations, both in SE Asia and in other malaria-endemic regions, including the Guiana Shield and the western Pacific (MalariaGEN, 2016; Menard et al., 2016; Das et al., 2019; WWARN, 2019; Mathieu et al., 2020; Miotto et al., 2020). Aside from C580Y, however, only a handful of K13 mutations (N458Y, M476I, Y493H, R539T, I543T and R561H) have been validated by gene-editing experiments as conferring resistance in vitro (Straimer et al., 2015; Siddiqui et al., 2020). Nonetheless, multiple other mutations in this gene have been associated with the clinical delayed clearance phenotype and have been proposed as candidate markers of ART resistance (WWARN, 2019; WHO, 2019).

Here, we define the role of a panel of K13 mutations identified in patient isolates, and address the key question of whether these mutations can confer resistance in African strains. We include the K13 R561H mutation, earlier associated with delayed parasite clearance in SE Asia (Ashley et al., 2014; Phyo et al., 2016), and very recently identified at up to 13% prevalence in certain districts in Rwanda (Uwimana et al., 2020; Bergmann et al., 2021; Uwimana et al., 2021). This study also enabled us to assess the impact of the parasite genetic background on in vitro phenotypes, including mutations in ferredoxin and mdr2 that were earlier associated with resistance (Miotto...
et al., 2015). Our results show that K13 mutations can impart ART resistance across multiple Asian and African strains, at levels that vary widely depending on the mutation and the parasite genetic background. Compared with K13 mutant Asian parasites, we observed stronger in vitro fitness costs in most K13-edited African strains, which might predict a slower dissemination of ART resistance in high-transmission African settings. Nonetheless, our data highlight the threat of the R561H mutation emerging in Rwanda, which confers elevated RSA resistance and minimal fitness cost in African 3D7 parasites.

Results

Non-synonymous K13 mutations are present at low frequencies in Africa

To examine the status of K13 mutations across Africa, we analyzed K13 beta-propeller domain sequences in 3,257 isolates from 11 malaria-endemic African countries, including The Gambia, Sierra Leone, and Burkina Faso in West Africa; Chad, Central African Republic, Republic of the Congo, and Equatorial Guinea in Central Africa; and Burundi, Tanzania, Rwanda, and Somalia in East Africa. Samples were collected between 2012 and 2019, with most countries sampled across multiple years. 1,038 (32%) originated from The Gambia, Republic of the Congo and Burundi and have not been previously reported, whereas the remaining samples including those from Rwanda have been published (Figure 1–Source data 1; Supplementary file 1).

Of all samples, 98% (3,179) were K13 wild-type, i.e. they matched the 3D7 (African) reference sequence or harbored a synonymous (non-coding) mutation. For individual countries, the percentage of K13 wild-type samples ranged from 95% to 100% (Figure 1; Figure 1–source data 1). In total, we identified 35 unique non-synonymous mutations in K13. Of these, only two have been validated as resistance mediators in the SE Asian Dd2 strain: the M476I mutation initially identified from long-term ART selection studies and the R561H mutation observed in SE Asia and Rwanda (Ariey et al., 2014; Straimer et al., 2015; Uwimana et al., 2020).

Of the 35 non-synonymous mutations, only two were present in >6 samples: R561H (n=20, found only in Rwanda, sampled from 2012 to 2015; (Uwimana et al., 2020)), and A578S (n=10; observed in four African countries across multiple years). Previously A578S was shown not to confer in vitro resistance in Dd2 (Menard
et al., 2016). In the set of 927 genotyped Rwandan isolates, R561H accounted for 44% of mutant samples and 2% of all samples (Figure 1 inset).

K13 R561H, M579I and C580Y mutations can confer in vitro artemisinin resistance in African parasites

To test whether R561H can mediate ART resistance in African strains, we developed a CRISPR/Cas9-mediated K13 editing strategy (Supplementary file 2) to introduce this mutation into 3D7 and F32 parasites. On the basis of whole-genome sequence analysis of African isolates, 3D7 was recently shown to segregate phylogenetically with parasites from Rwanda (Ariey et al., 2014; Uwimana et al., 2020). F32 was derived from an isolate from Tanzania (Witkowski et al., 2010). We also tested the C580Y mutation that predominates in SE Asia, as well as the M579I mutation earlier identified in a P. falciparum-infected migrant worker in Equatorial Guinea who displayed delayed parasite clearance following ACT treatment (Lu et al., 2017). The positions of these residues are highlighted in the K13 beta-propeller domain structure shown in Supplementary file 3. For 3D7, F32 and other lines used herein, their geographic origins and genotypes at drug resistance loci are described in Table 1 and Supplementary file 4. All parental lines were cloned by limiting dilution prior to transfection. Edited parasites were identified by PCR and Sanger sequencing, and cloned. These and other edited parasite lines used herein are described in Supplementary file 5.

RSAs, used to measure in vitro ART susceptibility, revealed a wide range of mean survival values for K13 mutant lines. For 3D7 parasites, the highest RSA survival rates were observed with 3D7^R561H parasites, which averaged 6.6% RSA survival. For the 3D7^M579I and 3D7^C580Y lines, mean RSA survival rates were both 4.8%, a 3 to 4-fold increase relative to the 3D7^WT line. No elevated RSA survival was seen in a 3D7 control line (3D7^ctrl) that expressed only the silent shield mutations used at the guide RNA cut site (Figure 2A; Figure 2–source data 1). Western blot analysis with tightly synchronized ring-stage parasites revealed a ~30% reduction in K13 protein expression levels in these three K13 mutant lines relative to the parental 3D7^WT (Figure 2–figure supplement 1; Figure 2–figure supplement 1–source data 1).

Interestingly, for F32 parasites the introduction of K13 mutations yielded no significant increase in RSA survival, whose rates were in the range of 0.3% to 0.5% for lines expressing R561H, M579I, C580Y or wild-type K13 (Figure 2B). Previously we reported that introduction of M476I into F32 parasites resulted in a modest gain of
resistance (mean survival of 1.7%) while this same mutation conferred RSA survival levels of ~10% in edited Dd2 parasites (Straimer et al., 2015). These data suggest that while K13 mutations differ substantially in their impact on ART susceptibility, there is an equally notable contribution of the parasite genetic background.

We next introduced M579I and C580Y into cloned Ugandan isolates UG659 and UG815. Editing of both mutations into UG659 yielded moderate RSA survival rates (means of 6.3% and 4.7% for UG659M579I or UG659C580Y respectively, vs. 1.0% for UG659WT; Figure 2C). These values resembled our results with 3D7. Strikingly, introducing K13 M579I or C580Y into UG815 yielded the highest rates of in vitro resistance, with mean survival levels reaching ~12% in both UG815M579I and UG815C580Y. These results were confirmed in a second independent clone of UG815M579I (Figure 2D). M579I and C580Y also conferred equivalent levels of resistance in edited Dd2 parasites (RSA survival rates of 4.0% and 4.7%, respectively; Figure 2–source data 1). These data show that mutant K13-mediated ART resistance in African parasites can be achieved, in some but not all strains, at levels comparable to or above those seen in SE Asian parasites.

K13 C580Y and M579I mutations, but not R561H, are associated with an in vitro fitness defect across African parasites

To examine the relation between resistance and fitness in African parasites harboring K13 mutations, we developed an in vitro fitness assay that uses quantitative real-time PCR (qPCR) for allelic discrimination. Assays were conducted by pairing K13 wild-type lines (i.e. 3D7, F32, UG659 and UG815) with their isogenic edited R561H, M579I, or C580Y counterparts.

Assays were initiated with tightly synchronized trophozoites, mixed in 1:1 ratios of wild-type to mutant isogenic parasites, and cultures were maintained over a period of 36 days (~18 generations of asexual blood stage growth). Cultures were sampled every four days for genomic DNA (gDNA) preparation and qPCR analysis. TaqMan probes specific to the K13 wild-type or mutant (R561H, M579I or C580Y) alleles were used to quantify the proportion of each allele.

Results showed that the K13 M579I and C580Y mutations each conferred a significant fitness defect across most strains tested, with the proportions of K13 mutant lines declining over time. For both mutations, the largest
reductions were observed with edited 3D7 or UG815 parasites. In contrast, these mutations exerted a minimal impact on fitness in UG659. For R561H, we observed no impact on fitness in 3D7 parasites, although in F32 this mutation exerted a fitness defect similar to M579I and C580Y (Figure 3A–D; Figure 3–source data 1). From these data, we calculated the fitness cost, which represents the percent reduction in growth rate per 48 h generation of a test line compared to its wild-type isogenic comparator. These costs ranged from <1% to 12% per generation across mutations and lines, with the lowest costs observed in 3D7$^{R561H}$ and UG659$^{C580Y}$, and the greatest cost observed with K13-edited UG815 lines (Figure 3E). Comparing data across these four African strains revealed that high RSA survival rates were generally accompanied by high fitness costs, and conversely that low fitness costs were associated with low survival rates. An exception was 3D7$^{R561H}$ that showed moderate resistance with no apparent fitness cost (Figure 3F).

The K13 C580Y mutation has swept rapidly across Cambodia, displacing other K13 variants

We next examined the spatio-temporal distribution of K13 alleles in Cambodia, the epicenter of ART resistance in SE Asia. In total, we analyzed the K13 propeller domain sequences from 3,327 parasite isolates collected from western, northern, eastern and southern Cambodian provinces (Figure 4–figure supplement 1). Samples were collected between 2001 and 2017, except for the southern region where sample collection was initiated in 2010. 1,412 samples (42%) were obtained and sequenced during the period 2015-2017 and have not previously been published. Earlier samples were reported in (Ariey et al., 2014; Menard et al., 2016). In sum, 19 nonsynonymous polymorphisms in K13 were identified across all regions and years. Of these, only three were present in >10 samples: Y493H (n=83), R539T (n=87) and C580Y (n=1,915). Each of these mutations was previously shown to confer ART resistance in vitro (Straimer et al., 2015). Rarer mutations included A418V, I543T, P553L, R561H, P574L, and D584V (Figure 4; Figure 4–source data 1).

This analysis revealed a significant proportion of K13 wild-type parasites in the early 2000s, particularly in northern and eastern Cambodia, where 96% of isolates in 2001-2002 were wild type (Figure 4). In western Cambodia, where ART resistance first emerged (Dondorp et al., 2009; Noedl et al., 2009), the wild-type allele percentage in 2001-2002 had already fallen to 56%. This is striking given that delayed parasite clearance following ACT or artesunate treatment was first documented in 2008-2009 (Noedl et al., 2008; Noedl et al., 2009).
In all four regions, the frequency of the wild-type allele declined substantially over time and the diversity of mutant alleles contracted, with nearly all wild-type and non-K13 C580Y mutant parasites being replaced by parasites harboring the C580Y mutation (Figure 4). This effect was particularly pronounced in the west and the south, where the prevalence of C580Y in 2016-17 effectively attained 100%, increasing from 22% and 58% respectively in the initial sample sets (Figure 4A, D). In northern and eastern Cambodia, C580Y also outcompeted all other mutant alleles; however, 19-25% of parasites remained K13 wild type in 2016-17 (Figure 4B, C). These data show rapid dissemination of K13 C580Y across Cambodia.

SE Asian K13 mutations associated with delayed parasite clearance differ substantially in their ability to confer artemisinin resistance in vitro

Given that most K13 polymorphisms present in the field have yet to be characterized in vitro, we selected a set of mutations to test by gene editing, namely E252Q, F446I, P553L, R561H and P574L (highlighted in Supplementary file 3). F446I is the predominant mutation in Myanmar (Imwong et al., 2020). P553L, R561H and P574L have each been shown to have multiple independent origins throughout SE Asia (Menard et al., 2016), and were identified at low frequencies in our sequencing study in Cambodia (Figure 4). Lastly, the E252Q mutation was formerly prevalent on the Thai-Myanmar border, and, despite its occurrence upstream of the beta-propeller domain, has been associated with delayed parasite clearance in vivo (Anderson et al., 2017; Cerqueira et al., 2017; WWARN, 2019).

Zinc-finger nuclease- or CRISPR/Cas9-based gene-edited lines expressing K13 E252Q, F446I, P553L, R561H or P574L were generated in Dd2 or Cam3.II lines expressing wild-type K13 (Dd2WT or Cam3.IIWT) and recombinant parasites were cloned. Early ring-stage parasites were then assayed for their ART susceptibility using the RSA. For comparison, we included published Dd2 and Cam3.II lines expressing either K13 C580Y (Dd2C580Y and Cam3.II C580Y) or R539T (Dd2R539T and the original parental line Cam3.II R539T) (Straimer et al., 2015), as well as control lines expressing only the guide-specific silent shield mutations (Dd2ctrl and Cam3.IIctrl).

Both the P553L and R561H mutations yielded mean RSA survival rates comparable to C580Y (4.6% or 4.3% RSA survival for Dd2P553L or Dd2R561H, respectively, vs 4.7% for Dd2C580Y; Figure 5A; Figure 5–source data 1).
F446I and P574L showed only modest increases in survival relative to the wild-type parental line (2.0% and 2.1% for Dd2\textsuperscript{F446I} and Dd2\textsuperscript{P574L}, respectively, vs 0.6% for Dd2\textsuperscript{WT}). No change in RSA survival relative to Dd2\textsuperscript{WT} was observed for the Dd2\textsuperscript{E252Q} line. The resistant benchmark Dd2\textsuperscript{R539T} showed a mean RSA survival level of 20.0%, consistent with earlier reports of this mutation conferring high-grade ART resistance \textit{in vitro} (Straimer et al., 2015; Straimer et al., 2017).

In contrast to Dd2, editing of the F446I, P553L and P574L mutations into Cambodian Cam3.II\textsuperscript{WT} parasites did not result in a statistically significant increase in survival relative to the K13 wild-type line, in part because the background survival rate of Cam3.II\textsuperscript{WT} was higher than for Dd2\textsuperscript{WT}. All survival values were <3%, contrasting with the Cam3.II\textsuperscript{R539T} parental strain that expresses the R539T mutation (~20% mean survival; Figure 5B; Figure 5–source data 1). The E252Q mutation did not result in elevated RSA survival in the Cam3.II background, a result also observed with Dd2. Nonetheless, ART resistance was apparent upon introducing the R561H mutation into Cam3.II\textsuperscript{WT} parasites, whose mean survival rates exceeded the Cam3.II\textsuperscript{C580Y} line (13.2% vs 10.0%, respectively). No elevated survival was seen in the Cam3.II\textsuperscript{ctrl} line expressing only the silent shield mutations used at the guide RNA cut site.

**SE Asian K13 mutations do not impart a significant fitness impact on Dd2 parasites**

Prior studies with isogenic gene-edited SE Asian lines have shown that certain K13 mutations can exert fitness costs, as demonstrated by reduced intra-erythrocytic asexual blood stage parasite growth (Straimer et al., 2017; Nair et al., 2018). To determine the fitness impact of the K13 mutations described above, we utilized an eGFP-based parasite competitive growth assay (Ross et al., 2018). Dd2\textsuperscript{E252Q}, Dd2\textsuperscript{F446I}, Dd2\textsuperscript{P553L}, Dd2\textsuperscript{R561H} or Dd2\textsuperscript{P574L} were co-cultured with an isogenic K13 wild-type eGFP\textsuperscript{+} Dd2 reporter line at a starting ratio of 1:1. The proportion of eGFP\textsuperscript{+} parasites was then assessed every two days. As controls, we included Dd2\textsuperscript{WT}, Dd2\textsuperscript{bsm} and Dd2\textsuperscript{C580Y}. These data provided evidence of a minimal impact with the F446I, P553L and C580Y mutations, with E252Q, R561H and P574L having greater fitness costs when compared to Dd2\textsuperscript{WT} (Figure 5C; Figure 5–figure supplement 1; Figure 5–source data 2). Both C580Y and P553L displayed elevated RSA survival and minimal fitness cost in the Dd2 strain, providing optimal traits for dissemination (Figure 5D). We note that all fitness costs in Dd2 were considerably lower than those observed in our four African strains (Figure 3).
Strain-dependent genetic background differences significantly impact RSA survival rates in culture-adapted Thai isolates

Given the earlier abundance of the R561H and E252Q alleles in border regions of Thailand and Myanmar, we next tested the impact of introducing these mutations into five Thai K13 wild-type isolates (Thai1-5). For comparison, we also edited C580Y into several isolates. These studies revealed a major contribution of the parasite genetic background in dictating the level of mutant K13-mediated ART resistance, as exemplified by the C580Y lines whose mean survival rates ranged from 2.1% to 15.4%. Trends observed for individual mutations were maintained across strains, with the R561H mutation consistently yielding moderate to high in vitro resistance at or above the level of C580Y. Consistent with our Dd2 results, introducing E252Q did not result in significant increases in survival rates relative to isogenic K13 wild-type lines (Figure 6A-E; Figure 6–source data 1).

We also profiled two unedited culture-adapted Thai isolates (Thai6E252Q and Thai7E252Q) that express the K13 E252Q mutation upstream of the propeller domain. Notably, both lines exhibited mean RSA survival rates significantly above the 1% threshold for ART sensitivity (2.7% for Thai6E252Q and 5.1% for Thai7E252Q; Figure 6F). These data suggest that additional genetic factors present in these two Thai isolates are required for E252Q to manifest ART resistance.

Mutations in the *P. falciparum* multidrug resistance protein 2 and ferredoxin genes do not modulate resistance to artemisinin or parasite fitness in vitro

In a prior genome-wide association study of SE Asian parasites, K13-mediated ART resistance was associated with D193Y and T484I mutations in the ferredoxin (fd) and multidrug resistance protein 2 (mdr2) genes, respectively (Miotto *et al.*, 2015). To directly test their role, we applied CRISPR/Cas9 editing (Supplementary file 6) to revert the fd D193Y and mdr2 T484I mutations to the wild-type sequences in the Cambodian strains RF7C580Y and Cam3.II C580Y, which both express K13 C580Y. Isogenic RF7C580Y parasites expressing the mutant or wild-type fd residue at position 193 showed no change in RSA survival rates, either at 700 nM (averaging ~27%), or across a range of DHA concentrations down to 1.4 nM (Figure 7A, C; Figure 7–figure supplement 1; Figure 7–source data 1). Editing fd D193Y into the recombinant CamWT C580Y line that expresses K13 C580Y (Straimer *et al.*, 2015) also had no impact on RSA survival (with mean RSA survival rates of 11-13%).
Likewise, Cam3.II C580Y parasites maintained the same rate of in vitro RSA survival (mean 19-22%) irrespective of their mdr2 allele. Silent shield mutations had no impact for either fd or mdr2. eGFP-based fitness assays initiated at different starting ratios of eGFP and either fd-edited RF7 C580Y or mdr2-edited Cam3.II C580Y lines revealed no change in the growth rates of the fd or mdr2 mutants compared with their wild-type controls (Figure 7B, D; Figure 7–figure supplement 1; Figure 7–source data 2 and 3). These data suggest that the fd D193Y and mdr2 T484I mutations are markers of ART-resistant founder populations but themselves do not contribute directly to ART resistance or augment parasite fitness.

Discussion

Mutant K13-mediated ART resistance has substantially compromised the efficacy of antimalarial treatments across SE Asia (Hanboonkunupakarn and White, 2020), and the relatively high prevalence of the R561H variant that has recently been associated with delayed clearance in Rwanda highlights the risk of ART resistance emerging and spreading in sub-Saharan Africa (Uwimana et al., 2020; Bergmann et al., 2021; Uwimana et al., 2021). Using gene editing and phenotypic analyses, we provide definitive evidence that the K13 R561H, M579I and C580Y mutations can confer in vitro ART resistance in several African strains. In vitro resistance, as defined using the RSA, was comparable between gene-edited K13 R561H 3D7 parasites (originating from or near Rwanda) and C580Y Dd2 and Cam3.II parasites (from SE Asia). Further investigations into edited African 3D7 parasites showed that these mutations also resulted in a ~30% decrease in K13 protein levels, consistent with earlier studies into the mechanistic basis of mutant K13-mediated ART resistance (Birnbaum et al., 2017; Siddiqui et al., 2017; Yang et al., 2019; Gnadig et al., 2020; Mok et al., 2021). We also observed that K13 mutant African strains differed widely in their RSA survival rates. As an example, when introduced into the Tanzanian F32 strain, the C580Y mutation yielded a 0.3% RSA survival rate (not resistant), contrasting with 11.8% survival (highly resistant) in the Ugandan UG815 strain. These data suggest that F32 parasites lack additional genetic determinants that are required for mutant K13 to confer ART resistance. Collectively, our results provide evidence that certain African strains present no major biological obstacle to becoming ART resistant in vitro upon acquiring K13 mutations. Further gene editing experiments are merited to extend these studies to additional African strains, and to incorporate other variants such as C469Y and A675V that are increasing in prevalence in Uganda (Asua et al., 2020).
Our mixed culture competition assays with African parasites revealed substantial fitness costs with the K13 C580Y mutation in three of the four strains tested (UG659 was the exception). The largest growth defect was observed with the edited UG815 C580Y line, which also yielded the highest level of ART resistance \textit{in vitro}. These data suggest that K13 C580Y may not easily take hold in Africa where, unlike in SE Asia, infections are often highly polyclonal, generating intra-host competition that impacts a strain’s ability to succeed at the population level. In addition, individuals in highly-endemic African settings generally have high levels of acquired immunity, potentially minimizing infection by relatively unfit parasites, and often have asymptomatic infections that go untreated, and are thus less subject to selective drug pressure, compared with individuals in SE Asia (Eastman and Fidock, 2009). This situation recalls the history of chloroquine use in Africa, where fitness costs caused by mutations in the primary resistance determinant PfCRT resulted in the rapid resurgence of wild-type parasites following the implementation of other first-line antimalarial therapies (Kublin \textit{et al.}, 2003; Laufer \textit{et al.}, 2006; Ord \textit{et al.}, 2007; Frosch \textit{et al.}, 2014).

An even greater fitness cost was observed with the M579I mutation, earlier detected in an infection acquired in Equatorial Guinea with evidence of \textit{in vivo} ART resistance (Lu \textit{et al.}, 2017) but which was notably absent in all 3,257 African samples reported herein. In contrast, we observed no evident fitness cost in 3D7 parasites expressing the R561H variant, which might help contribute to its increasing prevalence in Rwanda. While our Rwandan samples from 2012-2015 observed this mutation at 2% prevalence, samples collected by others in 2018 and 2019 identified this mutation at 12-13% prevalence (Bergmann \textit{et al.}, 2021; Uwimana \textit{et al.}, 2021). One of these reports included evidence associating R561H with delayed parasite clearance in patients treated with the ACT artemether-lumefantrine (Uwimana \textit{et al.}, 2021). These recent data heighten the concern that mutant K13 might be taking hold in certain areas in Africa where it can begin to compromise ACT efficacy.

In Cambodia, our spatio-temporal analysis of K13 sequence diversity highlights the initial emergence of C580Y in the western provinces, and its progressive replacement of other variants in the country. Interestingly, this mutation was already at high prevalence in western Cambodia several years before the first published reports of delayed parasite clearance in ART-treated patients (Noedl \textit{et al.}, 2008; Dondorp \textit{et al.}, 2009; Ariey \textit{et al.}, 2014). The success of this mutation in Cambodia, and elsewhere in the eastern Greater Mekong subregion (Imwong \textit{et al.}...
cannot be explained by resistance alone, as we previously reported that the less common R539T and
I543T variants conferred greater ART resistance \textit{in vitro} (Straimer \textit{et al.}, 2015). Similarly, we now report that the
R561H and P553L mutations yield equivalent degrees of ART resistance in Dd2 parasites when compared with
C580Y. In contrast, low-level resistance was observed with F446I, which has nonetheless spread across
Myanmar (Imwong \textit{et al.}, 2020). In a separate recent gene editing study, F446I yielded no significant \textit{in vitro}
resistance in 3D7 parasites and was fitness neutral (Siddiqui \textit{et al.}, 2020), consistent with our findings for this
mutation in edited Dd2 parasites.

Our studies into the impact of K13 mutations on \textit{in vitro} growth in Asian Dd2 parasites provide evidence that that
the C580Y mutation generally exerts less of a fitness cost relative to other K13 variants, as measured in K13-edited parasites co-cultured with an eGFP reporter line. A notable exception was P553L, which compared with
C580Y was similarly fitness neutral and showed similar RSA values. P553L has nonetheless proven far less
successful in its regional dissemination compared with C580Y (Menard \textit{et al.}, 2016). These data suggest that
additional factors have contributed to the success of C580Y in sweeping across SE Asia. These might include
specific genetic backgrounds that have favored the dissemination of C580Y parasites, possibly resulting in
enhanced transmission potential (Witmer \textit{et al.}, 2020), or ACT use that favored the selection of partner drug
resistance in these parasite backgrounds (van der Pluijm \textit{et al.}, 2019). In terms of growth rates in our isogenic
Dd2 lines, the most detrimental impacts were observed with E252Q and R561H, which earlier predominated
near the Thailand-Myanmar border region, but were later overtaken by C580Y (Phyo \textit{et al.}, 2016). In our study, C580Y produced an optimal combination of no measurable fitness cost and relatively high RSA survival rates in Dd2 parasites. In a prior independent study however, R561H showed slightly improved fitness relative to C580Y in paired isogenic parasites from Thailand (generated in the NHP4302 strain), providing further evidence that both fitness and resistance are strain-dependent (Nair \textit{et al.}, 2018).

Further research is also required to define secondary genetic determinants that could augment mutant K13-mediated ART resistance, and to explore other potential mediators of resistance. Proposed candidates have included \textit{fd}, \textit{mdr2}, \textit{ap-2u}, \textit{ubp1} and \textit{pfcoronin}, which have earlier been associated with \textit{P. falciparum} ART susceptibility (Demas \textit{et al.}, 2018; Henrici \textit{et al.}, 2019; Sutherland \textit{et al.}, 2020). Our data argue against a direct role for mutations in \textit{fd} and \textit{mdr2} in the strains tested herein. We also observed no evident association between
the genotypes of pfcr1, pfmdr1, arps10, ap-2µ or ubp1 and the degree to which mutant K13 conferred ART resistance in vitro in our set of African or Asian strains (Supplementary file 4). Mutations associated with enhanced DNA repair mechanisms have also been observed in ART-resistant SE Asian parasites, supporting the idea that mutant K13 parasites may have an improved ability to repair ART-mediated DNA damage (Xiong et al., 2020). Further studies are merited to investigate whether these DNA repair mutations may provide a favorable background for the development of ART resistance.

At the population level, we note that P. falciparum genomic structures in Africa tend to be far more diverse than in the epicenter of resistance in Cambodia, where parasite strains are highly sub-structured into a few lineages that can readily maintain complex genetic traits (Amato et al., 2018). A requirement to transmit mutant K13 and additional determinants of resistance in African malaria-endemic settings, where genetic outcrossing is the norm, would predict that ART resistance will spread more gradually in this continent than in SE Asia. It is nonetheless possible that secondary determinants will allow some African strains to offset fitness costs associated with mutant K13, or otherwise augment K13-mediated ART resistance. Identifying such determinants could be possible using genome-wide association studies or genetic crosses between ART-resistant and sensitive African parasites in the human liver-chimeric mouse model of P. falciparum infection (Vaughan et al., 2015; Amambua-Ngwa et al., 2019). Reduced transmission rates in areas of Africa where malaria is declining, leading to lower levels of immunity, may also benefit the emergence and dissemination of mutant K13 (Conrad and Rosenthal, 2019).

Another impediment to the dissemination of ART resistance in Africa is the continued potent activity of lumefantrine, the partner drug in the first line treatment artemether-lumefantrine (Conrad and Rosenthal, 2019). This situation contrasts with SE Asia where ART-resistant parasites have also developed high-level resistance to the partner drug PPQ, with widespread treatment failures enabling the dissemination of multidrug-resistant strains (Conrad and Rosenthal, 2019; van der Pluijm et al., 2019). While the genotyping data presented herein and other recent molecular surveillance studies reveal low prevalence of mutant K13 in Africa (Kayiba et al., 2020; Schmedes et al., 2021), the emergence and spread of the R561H variant in Rwanda is cause for significant concern. These data call for continuous continent-wide monitoring of the emergence and spread of
mutant K13 in Africa, and for studies into whether its emergence in Rwanda is a harbinger of subsequent partner drug resistance and ACT treatment failure.
## Key Resources Table

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Gene (Plasmodium falciparum 3D7 strain) | Kelch13 (K13) | PlasmoDB | PF3D7_1343700 |  |
| Gene (Plasmodium falciparum 3D7 strain) | Ferredoxin (fd) | PlasmoDB | PF3D7_1318100 |  |
| Gene (Plasmodium falciparum 3D7 strain) | Multidrug resistance protein 2 (mdr2) | PlasmoDB | PF3D7_1447900 |  |
| Strain, strain background (Plasmodium falciparum) | 3D7 clone A10 (3D7<sup>WT</sup>) | D. Goldberg, Washington University School of Medicine, St. Louis, MO, USA |  | see Table 1 and Supplementary file 4 for additional details on all *P. falciparum* strains employed herein |
| Strain, strain background (Plasmodium falciparum) | F32-TEM (F32<sup>WT</sup>) | F. Benoit-Vical, Université de Toulouse, Toulouse, France (Ariey et al., 2014) |  |  |
| Strain, strain background (Plasmodium falciparum) | UG659 (UG659<sup>WT</sup>) | P. Rosenthal, University of California, San Francisco, CA, USA |  |  |
| Strain, strain background (Plasmodium falciparum) | UG815 (UG815<sup>WT</sup>) | P. Rosenthal, University of California, San Francisco, CA, USA |  |  |
| Strain, strain background (Plasmodium falciparum) | Dd2 (Dd2<sup>WT</sup>) | The Malaria Research and Reference Reagent Resource Center (MR4), BEI Resources | MRA-156 |  |
| Strain, strain background (Plasmodium falciparum) | Cam3.II<sup>Rs39T</sup> | R. Fairhurst, NIAID, NIH, Bethesda, MD, USA (Straimer et al., 2015) | PH0306-C |  |
| Strain, strain background (Plasmodium falciparum) | CamWT | R. Fairhurst, NIAID, NIH, Bethesda, MD, USA (Straimer et al., 2015) | PH0164-C |
|-----------------------------------------------|-------|-----------------------------------------------------------------|----------|
| Strain, strain background (Plasmodium falciparum) | RF7 (RF7<sup>C580Y</sup>) | R. Fairhurst, NIAID, NIH, Bethesda, MD, USA (Ross et al., 2018) | PH1008-C |
| Strain, strain background (Plasmodium falciparum) | Thai<sup>1</sup>WT | T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA | TA32A2A4 |
| Strain, strain background (Plasmodium falciparum) | Thai<sup>2</sup>WT | T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA | TA50A2B2 |
| Strain, strain background (Plasmodium falciparum) | Thai<sup>3</sup>WT | T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA | TA85R1 |
| Strain, strain background (Plasmodium falciparum) | Thai<sup>4</sup>WT | T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA | TA86A3 |
| Strain, strain background (Plasmodium falciparum) | Thai<sup>5</sup>WT | T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA | NHP-01334-6B |
| Strain, strain background (Plasmodium falciparum) | Thai<sup>6</sup>E252Q | T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA | NHP4076 |
| Strain, strain background (Plasmodium falciparum) | Thai<sup>7</sup>E252Q | T. Anderson, Texas Biomedical Research Institute, San Antonio, TX, USA | NHP4673 |
| Strain, strain background (Escherichia coli) | HST08 | Takara | Cat. #636766 Stellar™ Competent Cells |
| Genetic reagent (Plasmodium falciparum) | Transgenic parasite lines | This study and (Straimer et al., 2015) | See Supplementary file 5 | Available from D. Fidock upon request |
|----------------------------------------|---------------------------|---------------------------------------|--------------------------|---------------------------------------|
| Commercial assay or kit                | In-Fusion® HD Cloning Plus kit | Takara                                | Cat. #638909             |                                       |
| Commercial assay or kit                | QuantiFast Multiplex PCR Kit | Qiagen                                 | Cat. #204654             |                                       |
| Sequence-based reagents                | Oligonucleotides           | This study                             | See Supplementary file 7 |                                       |
| Recombinant DNA reagents               | Plasmids                   | This study                             | See Supplementary file 8 | Available from D. Fidock upon request |
| Sequence-based reagents                | qPCR primers and probes    | This study                             | See Supplementary file 9 |                                       |
| Antibody                               | Anti-K13 (P. falciparum) (Mouse monoclonal) | I. Trakht, Columbia University Medical Center, New York, NY, USA (Gnadig et al., 2020) | Antibody clone E9 WB (1:1000) |                                       |
| Antibody                               | Anti-ERD2 (P. falciparum) (Rabbit polyclonal) | MR4, BEI Resources                     | MRA-1                    | WB (1:1000)                           |
| Antibody                               | StarBright Blue 700 goat anti-mouse | Bio-Rad                                | 12004158                 | WB (1:200)                            |
| Antibody                               | StarBright Blue 520 goat anti-rabbit | Bio-Rad                                | 12005869                 | WB (1:1000)                           |
| Other                                  | 4–20% Criterion™ TGX™ Precast Protein Gel | Bio-Rad                                | 5671093                  | Used with recommended buffers, also purchased from Bio-Rad |
| Chemical compound, drug                | Carbenicillin disodium salt | Sigma                                  | C1389                    |                                       |
| Chemical compound, drug                | WR99210                    | Jacobus Pharmaceuticals                 | D7439                    |                                       |
| Chemical compound, drug                | Dihydroartemisinin (DHA)   | Sigma                                  | D7439                    |                                       |
Sample collection and *K13* genotyping

Samples were obtained as blood-spot filter papers from patients seeking treatment at sites involved in national surveys of antimalarial drug resistance, or patients enrolled in therapeutic efficacy studies, or asymptomatic participants enrolled in surveillance programs. Collection details from African and Cambodian samples are provided in Figure 1–source data 1 and Figure 4–source data 1, respectively. Samples were processed at the Pasteur Institute in Paris or the Pasteur Institute in Cambodia, as detailed in Supplementary file 1. These investigators vouch for the accuracy and completeness of the molecular data. DNA was extracted from dried blood spots using QIAmp Mini kits, as described (Menard et al., 2016). A nested PCR was performed on each sample to amplify the *K13*-propeller domain, corresponding to codons 440-680. PCR products were sequenced using internal primers and electropherograms analyzed on both strands, using the Pf3D7_1343700 3D7 sequence as the wild-type reference. Quality controls included adding six blinded quality-control samples to each 96-well sequencing plate prepared from samples from each in-country partner and independently retesting randomly selected blood samples. Isolates with mixed alleles were considered to be mutated for the purposes of estimating the mutation frequencies.

*P. falciparum* parasite *in vitro* culture

*Plasmodium falciparum* asexual blood-stage parasites were cultured in human erythrocytes at 3% hematocrit in RPMI-1640 medium supplemented with 2 mM L-glutamine, 50 mg/L hypoxanthine, 25 mM HEPES, 0.21% NaHCO3, 10 mg/L gentamycin and 0.5% w/v Albumax II (Invitrogen). Parasites were maintained at 37°C in 5% O2, 5% CO2, and 90% N2. The geographic origin and year of culture adaptation for lines employed herein are described in Supplementary file 4. Parasite lines were authenticated by genotyping resistance genes and were screened by PCR for Mycoplasma every 3-6 months.
Whole-genome sequencing of parental lines

To define the genome sequences of our *P. falciparum* lines used for transfection, we lysed parasites in 0.05% saponin, washed them with 1×PBS, and purified genomic DNA (gDNA) using the QIAamp DNA Blood Midi Kit (Qiagen). DNA concentrations were quantified by NanoDrop (Thermo Scientific) and Qubit (Invitrogen) prior to sequencing. 200 ng of gDNA was used to prepare sequencing libraries using the Illumina Nextera DNA Flex library prep kit with dual indices. Samples were multiplexed and sequenced on an Illumina MiSeq to obtain 300 bp paired-end reads at an average of 50× depth of coverage. Sequence reads were aligned to the *P. falciparum* 3D7 reference genome (PlasmoDB version 36) using Burrow-Wheeler Alignment. PCR duplicates and unmapped reads were filtered out using Samtools and Picard. Reads were realigned around indels using GATK RealignerTargetCreator and base quality scores were recalibrated using GATK BaseRecalibrator. GATK HaplotypeCaller (version 3.8) was used to identify all single nucleotide polymorphisms (SNPs). These SNPs were filtered based on quality scores (variant quality as function of depth QD > 1.5, mapping quality > 40, min base quality score > 18) and read depth (> 5) to obtain high-quality SNPs, which were annotated using snpEFF. Integrated Genome Viewer was used to visually verify the presence of SNPs. BIC-Seq was used to check for copy number variations using the Bayesian statistical model (Xi et al., 2011). Copy number variations in highly polymorphic surface antigens and multi-gene families were removed as these are prone to stochastic changes during *in vitro* culture.

Whole-genome sequencing data were used to determine the genotypes of the antimalarial drug resistance loci *pfcr*, *mdr1*, *dhfr* and *dhps* (Haldar et al., 2018). We also genotyped *fd*, *arps10*, *mdr2*, *ubp1*, and *ap-2μ*, which were previously associated with ART resistance (Henriques et al., 2014; Miotto et al., 2015; Cerqueira et al., 2017; Adams et al., 2018). These results are described in Supplementary file 4.

Cloning of *K13, fd* and *mdr2* plasmids

Zinc-finger nuclease-meditated editing of select mutations in the *K13* locus was performed as previously described (Straimer et al., 2015). CRISPR/Cas9 editing of *K13* mutations was achieved using the pDC2-cam-coSpCas9-U6-gRNA-*dhfr* all-in-one plasmid that contains a *P. falciparum* codon-optimized Cas9 sequence, a human dihydrofolate reductase (*dhfr*) gene expression cassette (conferring resistance to WR99210) and restriction enzyme insertion sites for the guide RNA (gRNA) and donor template (White et al., 2019). A K13
propeller domain-specific gRNA was introduced into this vector at the BbsI restriction sites using the primer pair p1+p2 (Supplementary file 7) using T4 DNA ligase (New England BioLabs). Oligos were phosphorylated and annealed prior to cloning. A donor template consisting of a 1.5 kb region of the K13 coding region including the entire propeller domain was amplified using the primer pair p3+p4 and cloned into the pGEM T-easy vector system (Promega). This donor sequence was subjected to site-directed mutagenesis in the pGEM vector to introduce silent shield mutations at the Cas9 cleavage site using the primer pair p5+p6, and to introduce allele-specific mutations using primer pairs (p7 to p20). K13 donor sequences were amplified from the pGEM vector using the primer pair p21+p22 and sub-cloned into the pDC2-cam-coSpCas9-U6-gRNA-hdhfr plasmid at the EcoRI and AatII restriction sites by In-Fusion Cloning (Takara). Final plasmids (see Supplementary file 8) were sequenced using primers p23 to p25. A schematic showing the method of K13 plasmid construction can be found in Supplementary file 2. Both our customized zinc-finger nuclease and CRISPR/Cas9 approaches generated the desired amino acid substitutions without the genomic integration of any plasmid sequences or any additional amino acid changes in the K13 locus, and thus provide fully comparable data.

CRISPR/Cas9 editing of fd and mdr2 was performed using a separate all-in-one plasmid, pDC2-cam-Cas9-U6-gRNA-hdhfr, generated prior to the development of the codon-optimized version used above for K13 (Lim et al., 2016). Cloning was performed as for K13, except for gRNA cloning that was performed using In-Fusion cloning (Takara) rather than T4 ligase. Cloning of gRNAs was performed using primer pair p29+p30 for fd and p42+p43 for mdr2. Donor templates were amplified and cloned into the final vector using the primer pairs p31+p32 for fd and p44+p45 for mdr2. Site-directed mutagenesis was performed using the allele-specific primer pairs p33+p34 or p35+p36 for fd, and p46+p47 or p48+p49 for mdr2. All final plasmids (for both fd and mdr2, see Supplementary file 8) were sequenced using the primer pair p37+p38 (Supplementary file 7). Schematic representations of final plasmids are shown in Supplementary file 6.

Generation of K13, fd and mdr2 gene-edited parasite lines

Gene-edited lines were generated by electroporating ring-stage parasites at 5-10% parasitemia with 50 μg of purified circular plasmid DNA resuspended in Cytomix. Transfected parasites were selected by culturing in the presence of WR99210 (Jacobus Pharmaceuticals) for six days post electroporation. Parental lines harboring 2-3 mutations in the P. falciparum dihydrofolate reductase (dhfr) gene were exposed to 2.5 nM WR99210, while
Parasites harboring four dhfr mutations were selected under 10 nM WR99210 (see Supplementary file 4 for dhfr genotypes of transfected lines). Parasite cultures were monitored for recrudescence by microscopy for up to six weeks post electroporation. To test for successful editing, the K13 locus was amplified directly from parasitized whole blood using the primer pair p26+p27 (Supplementary file 7) and the MyTaq™ Blood-PCR Kit (Bioline). Primer pairs p39+p40 and p50+p51 were used to amplify fd and mdr2, respectively. PCR products were submitted for Sanger sequencing using the PCR primers as well as primer p28 in the case of K13, p41 (fd) or p52 (mdr2). Bulk-transfected cultures showing evidence of editing by Sanger sequencing were cloned by limiting dilution. All gene-edited transgenic lines generated herein are described in Supplementary file 5.

Parasite synchronization, ring-stage survival assays (RSAs) and flow cytometry

Synchronized parasite cultures were obtained by exposing predominantly ring-stage cultures to 5% D-Sorbitol (Sigma) for 15 min at 37°C to remove mature parasites. After 36 h of subsequent culture, multinucleated schizonts were purified over a density gradient consisting of 75% Percoll (Sigma). Purified schizonts were incubated with fresh RBCs for 3h, and early rings (0-3 hours post invasion; hpi) were treated with 5% D-Sorbitol to remove remaining schizonts.

In vitro RSAs were conducted as previously described, with minor adaptations (Straimer et al., 2015). Briefly, tightly synchronized 0-3 hpi rings were exposed to a pharmacologically-relevant dose of 700 nM DHA or 0.1% dimethyl sulfoxide (DMSO; vehicle control) for 6 h at 1% parasitemia and 2% hematocrit, washed three times with RPMI medium to remove drug, transferred to fresh 96-well plates, and cultured for an additional 66 h in drug-free medium. Removal of media and resuspension of parasite cultures was performed on a Freedom Evo 100 liquid-handling instrument (Tecan). Parasitemias were measured at 72 h by flow cytometry (see below) with at least 50,000 events captured per sample. Parasite survival was expressed as the percentage value of the parasitemia in DHA-treated samples divided by the parasitemia in DMSO-treated samples processed in parallel. We considered any RSA mean survival rates <2% to be ART sensitive.

Flow cytometry was performed on an BD Accuri™ C6 Plus cytometer with a HyperCyt plate sampling attachment (IntelliCyt), or on an iQue3® Screener Plus cytometer (Sartorius). Cells were stained with 1×SYBR Green (ThermoFisher) and 100 nM MitoTracker DeepRed (ThermoFisher) for 30 min and diluted in 1×PBS prior to analysis.
to sampling. Percent parasitemia was determined as the percentage of MitoTracker positive and SYBR Green-positive cells. For RSAs, >50,000 events were captured per well.

Western blot analysis of K13 expression levels in edited lines

Western blots were performed with lysates from tightly synchronized rings harvested 0-6 h post invasion. Parasite cultures were washed twice in ice-cold 1× phosphate-buffered saline (PBS), and parasites isolated by treatment with 0.05% saponin in PBS. Released parasites were lysed in 4% SDS, 0.5% Triton X-100 and 0.5% PBS supplemented 1× protease inhibitors (Halt Protease Inhibitors Cocktail, ThermoFisher). Samples were centrifuged at 14,000 rpm for 10 min to pellet cellular debris. Supernatants were collected and protein concentrations were determined using the DC protein assay kit (Bio-Rad). Laemmli Sample Buffer (Bio-Rad) was added to lysates and samples were denatured at 90°C for 10 min. Proteins were electrophoresed on precast 4-20% Tris-Glycine gels (Bio-Rad) and transferred onto nitrocellulose membranes. Western blots were probed with a 1:1000 dilution of primary antibodies to K13 (Gnadig et al., 2020) or the loading control ERD2 (BEI Resources), followed by a 1:200 dilution of fluorescent StarBright secondary antibodies (Bio-Rad). Western blots were imaged on a ChemiDoc system (Bio-Rad) and band intensities quantified using ImageJ.

TaqMan allelic discrimination real-time (quantitative) PCR-based fitness assays

Fitness assays with African K13-edited parasite lines were performed by co-culturing isogenic wild-type unedited and mutant edited parasites in 1:1 ratios. Assays were initiated with tightly synchronized trophozoites. Final culture volumes were 3 mL. Cultures were maintained in 12-well plates and monitored every four days over a period of 36 days (18 generations) by harvesting at each time point a fraction of each co-culture for saponin lysis. gDNA was then extracted using the QIAamp DNA Blood Mini Kit (Qiagen). The percentage of the wild-type or mutant allele in each sample was determined in TaqMan allelic discrimination real-time PCR assays. TaqMan primers (forward and reverse) and TaqMan fluorescence-labeled minor groove binder probes (FAM or HEX, Eurofins) are described in Supplementary file 9. Probes were designed to specifically detect the K13 R561H, M579I or C580Y propeller mutations. The efficiency and sensitivity of the TaqMan primers was assessed using standard curves comprising 10-fold serially diluted templates ranging from 10 ng to 0.001 ng. Robustness was demonstrated by high efficiency (88-95%) and R² values (0.98-1.00). The quantitative accuracy in genotype calling was assessed by performing multiplex qPCR assays using mixtures of wild-type and mutant
plasmids in fixed ratios (0:100, 20:80, 40:60, 50:50, 60:40, 80:20, 100:0). Triplicate data points clustered tightly, indicating high reproducibility in the data across the fitted curve ($R^2 = 0.89$ to 0.91).

Purified gDNA from fitness co-cultures was subsequently amplified and labeled using the primers and probes described in Supplementary file 9. qPCR reactions for each sample were run in triplicate. 20 μL reactions consisted of 1×QuantiFAST reaction mix containing ROX reference dye (Qiagen), 0.66 μM of forward and reverse primers, 0.16 μM FAM-MGB and HEX-MGB TaqMan probes, and 10 ng genomic DNA. Amplification and detection of fluorescence were carried out on a QuantStudio 3 qPCR machine (Applied Biosystems) using the genotyping assay mode. Cycling conditions were as follows: 30s at 60°C; 5 min at 95°C; and 40 cycles of 30s at 95°C and 1 min at 60°C for primer annealing and extension. Every assay was run with positive controls (wild-type or mutant plasmids at different fixed ratios). No-template negative controls (water) in triplicates were processed in parallel. Rn, the fluorescence of the FAM or HEX probe, was normalized to the fluorescence signal of the ROX reporter dye. Background-normalized fluorescence (Rn minus baseline, or ΔRn) was calculated as a function of cycle number.

To determine the wild-type or mutant allele frequency in each sample, we first confirmed the presence of the allele by only retaining values where the threshold cycle ($C_t$) of the sample was less than the no-template control by at least three cycles. Next, we subtracted the ΔRn of the samples from the background ΔRn of the no-template negative control. We subsequently normalized the fluorescence to 100% using the positive control plasmids to obtain the percentage of the wild-type and mutant alleles for each sample. The final percentage of the mutant allele was defined as the average of these two values: the normalized percentage of the mutant allele, and 100% minus the normalized percentage of the wild-type allele.

**eGFP-based fitness assays**

Fitness assays with Dd2, RF7$^{C580Y}$ and Cam3.II parasite lines were performed using mixed culture competition assays with an eGFP-positive (eGFP+) Dd2 reporter line (Ross et al., 2018). This reporter line uses a calmodulin promoter sequence to express high levels of GFP and includes human dhfr and blasticidin S-deaminase expression cassettes. This line was earlier reported to have a reduced rate of growth relative to parental non-recombinant Dd2, presumably at least in part because of its high levels of GFP expression (Ross et al., 2018;
Dhingra et al., 2019). With our Dd2 parasites, K13-edited lines were co-cultured in 1:1 ratios with the reporter line. This ratio was adjusted to 10:1 or 100:1 for fd-edited RF7<sup>C580Y</sup> and mdr2-edited Cam3.II parasites relative to the eGFP line, given the slower rate of growth with RF7<sup>C580Y</sup> and Cam3.II. Fitness assays were initiated with tightly synchronized trophozoites in 96-well plates, with 200 µL culture volumes. Percentages of eGFP<sup>+</sup> parasites were monitored by flow cytometry every two days over a period of 20 days (10 generations). Flow cytometry was performed as written above, except that only 100 nM MitoTracker DeepRed staining was used to detect total parasitemias, since SYBR Green and eGFP fluoresce in the same channel.

**Fitness Costs**

The fitness cost associated with a line expressing a given K13 mutation was calculated relative to its isogenic wild-type counterpart using the following equation:

\[
P' = P((1 - x)^n)
\]

where \( P' \) is equal to the parasitemia at the assay endpoint, \( P \) is equal to the parasitemia on day 0, \( n \) is equal to the number of generations from the assay start to finish, and \( x \) is equal to the fitness cost. This equation assumes 100% growth for the wild-type comparator line. For qPCR and GFP-based fitness assays, days 36 and 20 were set as the assay endpoints, resulting in the number of parasite generations (\( n \)) being set to 18 and 10, respectively.

**Ethics statement**

Health care facilities were in charge of collecting anonymized *P. falciparum* positive cases. Identification of individuals cannot be established. The studies were approved by ethics committees listed in Supplementary file 1. We note that the sponsors had no role in the study design or in the collection or analysis of the data. There was no confidentiality agreement between the sponsors and the investigators.

**Acknowledgments**

We thank Dr. Pascal Ringwald (World Health Organization) for his support and feedback. DAF gratefully acknowledges the US National Institutes of Health (R01 AI109023), the Department of Defense (W81XWH1910086) and the Bill & Melinda Gates Foundation (OPP1201387) for their financial support. BHS
was funded in part by T32 AI106711 (PD: D. Fidock). SM is a recipient of a Human Frontiers of Science Program Long-Term Fellowship. CHC was supported in part by the NIH (R01 AI121558; PI: Jonathan Juliano). FN is supported by the Wellcome Trust of Great Britain (Grant ID: 106698). TJCA acknowledges funding support from the NIH (R37 AI048071). DAF and DM gratefully acknowledge the World Health Organization for their funding. We thank the following individuals for their kind help with the K13-genotyped samples – Chad: Ali S. Djiddi, Mahamat S. I. Dior, Kodbessé Boulotigam, Mbanga Djimadoum, Hamit M. Alio, Mahamat M. H. Taisso, Issa A. Haggar; Burkina Faso: TES 2017-2018 team and the US President’s Malaria Initiative through the Improving Malaria Care Project as the funding agency for the study in Burkina Faso, Chris-Boris G. Panté-Wockama; Burundi: Dismas Baza; Tanzania: Mwaka Kakolwa, Celine Mandara, Tanzania TES coordination team for the Ministry of Health; Sierra Leone: Anitta R. Y. Kamara, Foday Sahr, Mohamed Samai; The Gambia: Balla Kandeh, Joseph Okebe, Serign J. Ceesay, Baboucarr Babou, Emily Jagne, Alsan Jobe; Congo: Brice S. Pembet, Jean M. Youndouka; Somalia: Jamal Ghilah Hefzullah Amran, Abdillahi Mohamed Hassan, Abdikarim Hussein Hassan and Ali Abdulrahman; Rwanda: extended TES team for the Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre.

Competing interests

MW is a former staff member of the World Health Organization. MW alone is responsible for the views expressed in this publication, which do not necessarily represent the decisions, policies or views of the World Health Organization. The other authors declare that no competing interests exist.
References

Adams T, Ennuson NAA, Quashie NB, Futagbi G, Matrevi S, Hagan OCK, Abuaku B, Koram KA, Duah NO. 2018. Prevalence of Plasmodium falciparum delayed clearance associated polymorphisms in adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific protease 1 (pfubp1) genes in Ghanaian isolates. Parasit Vectors 11:175. DOI: https://doi.org/10.1186/s13071-018-2762-3. PMID: 29530100

Amambua-Ngwaa A, Amenga-Etego L, Kamau E, Amato R, Ghansah A, Golassa L, Randrianarivelosojosa M, Ishengoma D, Apinjoh T, Maiga-Ascofare O, Andagalu B, Yavo W, Bouyou-Akotet M, Kolapo O, Mane K, Worwui A, Jeffries D, Simpson V, D’Alessandro U, Kwiatkowski D, Djimde AA. 2019. Major subpopulations of Plasmodium falciparum in sub-Saharan Africa. Science 365:813-816. DOI: https://doi.org/10.1126/science.aav5427. PMID: 31439796

Amato R, Pearson RD, Almagro-Garcia J, Amarantunga C, Lim P, Suon S, Sreng S, Drury E, Stalker J, Miotto O, Fairhurst RM, Kwiatkowski DP. 2018. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis 18:337-345. DOI: https://doi.org/10.1016/S1473-3099(18)30068-9. PMID: 29393911

Anderson TJ, Nair S, McDew-White M, Cheeseman IH, Nkhoma S, Bilgic F, McGready R, Ashley E, Pyae Phy A, White NJ, Nosten F. 2017. Population parameters underlying an ongoing soft sweep in Southeast Asian malaria parasites. Mol Biol Evol 34:131-144. DOI: https://doi.org/10.1093/molbev/msw228. PMID: 28025270

Ariey F, Witkowski B, Amarantunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chour CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50-55. DOI: https://doi.org/10.1038/nature12876. PMID: 24352242

Ashley EA, Dhorda M, Fairhurst RM, Amarantunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chour CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutsada K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olasebikan RR, Folaranmi AO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyombo MA, Fanelli CI, Tshefu AK, Mitha N, Valecha N, Phy A, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJF, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ, Tracking Resistance to Artemisinin Medicines. Emerg Infect Dis 27:294-296. DOI: https://doi.org/10.3201/eid2701.203527. PMID: 33505925

Asua V, Conrad MD, Aydemir O, Duvalsiat M, Legac J, Duarte E, Tumwebaze P, Chin DM, Cooper RA, Yeka A, Kamya MR, Dorsey G, Nsobya SL, Bailey J, Rosenthal PJ. 2020. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J Infect Dis 223:985-994. DOI: https://doi.org/10.1093/infectdis/jiaa687. PMID: 33146722

Bergmann C, van Loon W, Habarugira F, Tacoli C, Jager JC, Savelsberg D, Nshimiyumana F, Rwamugera E, Mbarusimana D, Ndoli J, Sendegaya A, Bayingana C, Mockenhaupt FP. 2021. Increase in Kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerg Infect Dis 27:294-296. DOI: https://doi.org/10.3201/eid2701.203527. PMID: 33505925

Birnbaum J, Flemming S, Reichard N, Soares AB, Mesen-Ramirez P, Jonscher E, Bergmann B, Spielmann T. 2017. A genetic system to study Plasmodium falciparum protein function. Nat Methods 14:450-456. DOI: https://doi.org/10.1038/nmeth.4223. PMID: 28288121

Birnbaum J, Scharf S, Schmidt S, Jonscher E, Hoeijmakers WAM, Flemming S, Toenhage CG, Schmitt M, Sabitzki R, Bergmann B, Frohlikhe M, Mesen-Ramirez P, Blancke Soares A, Herrmann H, Bartfai R, Spielmann T. 2020. A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites. Science 367:51-59. DOI: https://doi.org/10.1126/science.aax7435. PMID: 31896710

Cerqueira GC, Cheeseman IH, Schaffner SF, Nair S, McDew-White M, Phy A, Ashley EA, Melnikov A, Rogov P, Birren BW, Nosten F, Anderson TJ, Neafsey DE. 2017. Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. Genome Biol 18:78. DOI: https://doi.org/10.1186/s13059-017-1204-4. PMID: 28454557
Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van
Demas AR, Sharma AI, Wong W, Early AM, Redmond S, Bopp S, Neafsey DE, Volkman SK, Hartl DL, Wirth
Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, van Schalkwyk DA, Sawa P, Omar
Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio JJ. 2014. Genome editing in the
human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol
Phenotype Study Group Pukrittayakamee S, Day NPJ, Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, L
Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, Dzinjalamala FK, Plowe
CV. 2014. Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon
P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 365:455-467. DOI: https://doi.org/10.1056/NEJMoa0808859. PMID: 19641202
Eastman RT, Fidock DA. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate
malaria. Nat Rev Microbiol 7:864-874. DOI: https://doi.org/10.1038/nrmicro2239. PMID: 19881520
Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, Dzinjalamala FK, Plowe
CV. 2014. Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis
210:1110-1114. DOI: https://doi.org/10.1093/infectdis/iju216. PMID: 24723474
Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio JJ. 2014. Genome editing in the
human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol
32:819-821. DOI: https://doi.org/10.1038/nbt.2925. PMID: 24880488
Gnadig NF, Stokes BH, Edwards RL, Kalantarov GF, Heimsch KC, Kuderjavy M, Crane A, Lee MCS, Straimer
J, Becker K, Trakht IN, Odom John AR, Mok S, Fidock DA. 2020. Insights into the intracellular
localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13.
PLoS Pathog 16:e1008482. DOI: https://doi.org/10.1371/journal.ppat.1008482. PMID: 32310999
WWARN K13 Genotype-Phenotype Study Group. 2019. Association of mutations in the Plasmodium falciparum
Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a
WWARN individual patient data meta-analysis. BMC Med 17:1. DOI: https://doi.org/10.1186/s12916-
018-1207-3. PMID: 30651111
Haldar K, Bhattacharjee S, Safeukui I. 2018. Drug resistance in Plasmodium. Nat Rev Microbiol 16:156-170.
DOI: https://doi.org/10.1038/nrrevmicrobiol.2017.161. PMID: 29355852
Hanboonkunupakarn B, White NJ. 2020. Advances and roadblocks in the treatment of malaria. Br J Clin
Pharmacol Jul 12. DOI: https://doi.org/10.1111/bcp.14474. PMID: 32656850
Henrici RC, van Schalkwyk DA, Sutherland CJ. 2019. Modification of pfap2mu and pfubp1 markedly reduces
ring-stage susceptibility of Plasmodium falciparum to artemisinin in vitro. Antimicrob Agents Chemother
64. DOI: https://doi.org/10.1128/AAC.01542-19. PMID: 31636063
Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, van Schalkwyk DA, Sawa P, Omar
SA, Clark TG, Bousema T, Sutherland CJ. 2014. Directional selection at the pfmdr1, pfcr, pfubp1, and
pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis 210:2001-
2008. DOI: https://doi.org/10.1093/infdis/iju358. PMID: 24994911
Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, Suwannasin K, Kunasol C, Srisutham S,
Sanupratama J, Vongpromek R, Promnarate C, Saejeng A, Khantikul N, Sugaram R, Thanapongpichat S, SawanJuanaroen S, Sutawong K, Han KT, Htu Y, Linn K, Win AA, Hlaing TM, van
der Pluim RM, Mayxay M, Pongvongs M, Phommasone K, Triprua R, Peto TJ, von Seideling L, Nguon
C, Lek D, Chan XHS, Rekol H, Leang R, Huch C, Kwiatkowski DP, Miotto O, Ashley EA, Kyaw MP,
Pukrittayakamee S, Day NPJ, Dondorp AM, Smithuis FM, Nosten FH, White NJ. 2020. Molecular
epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational
study. Lancet Infect Dis 20:1470-1480. DOI: https://doi.org/10.1016/S1473-3099(20)30228-0. PMID:
32679084
Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van
der Pluim RM, Triprua R, Miotto O, Menard D, Dhorda M, Day NPJ, White NJ, Dondorp AM. 2017. The
spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular
epidemiology observational study. Lancet Infect Dis 17:491-497. DOI: https://doi.org/10.1016/S1473-
3099(17)30048-8. PMID: 28161569
Kayibá NK, Yobi DM, Tshibangu-Kabamba E, Tuan VP, Yamaoka Y, Devleesschauwer B, Mvumbi DM, Okitolonda Wemakoy E, De Mol P, Mvumbi GL, Hayette MP, Rosas-Aguirre A, Speybroeck N. 2020. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review. *Lancet Infect Dis* 21:e82-e92. DOI: https://doi.org/10.1016/S1473-3099(20)30493-X. PMID: 33125913

Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV. 2003. Re-emergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. *J Infect Dis* 187:1870-1875. DOI: https://doi.org/10.1086/375419. PMID: 12792863

Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalama FA, Takala SL, Taylor TE, Plowe CV. 2006. Return of chloroquine antimalarial efficacy in Malawi. *N Engl J Med* 355:1959-1966. DOI: https://doi.org/10.1056/NEJMoa1612765. PMID: 17093247

Lim MY, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A, Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PC, Yeung BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P. 2016. UDP-galactose and acetyl-CoA transporters as *Plasmodium* multidrug resistance genes. *Nat Microbiol* 1:1616. DOI: https://doi.org/10.1038/nmicrobiol.2016.166. PMID: 27642791

Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, Zhu G, Tang J, Liu Y, Wang W, Cao Y, Xu S, Gu Y, Li J, Zhang C, Gao Q, Menard D, Pain A, Yang H, Zhang Q, Cao J. 2017. Emergence of indigenous artemisinin-resistant *Plasmodium falciparum* in Africa. *N Engl J Med* 376:991-993. DOI: https://doi.org/10.1056/NEJMoa1612765. PMID: 28225668

MalariaGEN *Plasmodium falciparum* Community Project. 2016. Genomic epidemiology of artemisinin resistant malaria. *eLife* 5:e08714. DOI: https://doi.org/10.7554/eLife.08714. PMID: 26943619

Mathieu LC, Cox H, Early AM, Mok S, Lazrek Y, Paquet JC, Ade MP, Lucchi NW, Grant Q, Udhayakumar V, Alexandre JS, Demar M, Ringwald P, Neafsey DE, Fidock DA, Musset L. 2020. Local emergence in Amazonia of *Plasmodium falciparum* k13 C580Y mutants associated with *in vitro* artemisinin resistance. *eLife* 9:e51015. DOI: https://doi.org/10.7554/eLife.51015. PMID: 32394893

Menard K, Khim N, Bregnha J, Adegnika AA, Shafiul-Alam M, Amoudi O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Thakur GD, Dieye A, Djalle D, Dorkenoo MA, Eboumba-Moukoko CE, Espino FE, Fandeur T, Ferreira-da-Cruz MF, Fola AA, Fuehrer HP, Hassan AM, Herrera S, Hongvanthong B, Houze S, Ibrahim ML, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremser PG, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati JB, Menard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niare K, Noedl H, Ouedraogo JB, Pillai DR, Pradines B, Quang-Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh-Omar A, Silue KD, Sirima SB, Sutherland C, Syafruddin D, Tahar R, Tang LH, Toure OA, Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale JC, Stokes B, Straimer J, Witkowski B, Fidock DA, Rogier C, Ringwald P, Arife Y, Mercereau-Puijalon O, Karma Consortium. 2016. A worldwide map of *Plasmodium falciparum* K13-propeller polymorphisms. *N Engl J Med* 374:2453-2464. DOI: https://doi.org/10.1056/NEJMoa1513137. PMID: 27332904

Miotti O, Amato R, Ashley EA, Maclnnis B, Almagro-Garcia J, Amarangona C, Lim P, Mead D, Oyola SO, Dhorda M, Imwong M, Woodrow C, Manske M, Stalker J, Drury E, Campino S, Amenga-Etego L, Thanh TN, Tran HT, Ringwald P, Bethell D, Nosten F, Phylo AP, Chotivanich K, Chuar CM, Nguon C, Suon S, Newton PN, Mayxay M, Khanthavong M, Hongvanthong B, Htut Y, Han KT, Kyaw MP, Faiz MA, Fanelli CI, Onyamboko M, Mokuolu OA, Jacob CG, Takala-Harrison S, Plowe CV, Day NP, Dondorp AM, Spencer CC, McVean G, Fairhurst RM, White NJ, Kwiatkowski DP. 2015. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet* 47:226-234. DOI: https://doi.org/10.1038/ng.3189. PMID: 25599401

Miotti O, Sekihara M, Tachibana S, Yamauchi M, Pearson RD, Amato R, Goncalves S, Mehrara S, Noviyanti R, Marfurt J, Aubrun S, Price RN, Mueller I, Ikeda M, Mori T, Hirai M, Tavul L, Hetzel MW, Laman M, Barry AE, Ringwald P, Ohashi J, Hombhanje F, Kwiatkowski DP, Mita T. 2020. Emergence of artemisinin-resistant *Plasmodium falciparum* with kelch13 C580Y mutations on the island of New Guinea. *PLoS Pathog* 16:e1009133. DOI: https://doi.org/10.1371/journal.ppat.1009133. PMID: 33320907

Mok S, Stokes BH, Gnadig NF, Ross LS, Yeo T, Amarangona C, Allman E, Soljakov L, Bottrill AR, Tripathi J, Fairhurst RM, Llinas M, Bozdech Z, Tobin AB, Fidock DA. 2021. Artemisinin-resistant K13 mutations rewire *Plasmodium falciparum*’s intra-erythrocytic metabolic program to enhance survival. *Nat Commun* 12:530. DOI: https://doi.org/10.1038/s41467-020-20805-w. PMID: 33483501
Nair S, Li X, Arya GA, McDew-White M, Ferrari M, Nosten F, Anderson TJ. 2018. Do fitness costs explain the rapid spread of kelch13-C580Y substitutions conferring artemisinin resistance? *Antimicrob Agents Chemother* **62**:e00605-00618. DOI: https://doi.org/10.1128/AAC.00605-18. PMID: 29914983

Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* **359**:2619-2620. DOI: https://doi.org/10.1056/NEJMoa0805011. PMID: 19064625

Noedl H, Socheat D, Satimai W. 2009. Artemisinin-resistant malaria in Asia. *N Engl J Med* **361**:540-541. DOI: https://doi.org/10.1056/NEJMc0900231. PMID: 19641219

Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G, Drakeley CJ, Sutherland CJ. 2007. Seasonal carriage of *pfcrt* and *pfmdr1* alleles in Gambian *Plasmodium falciparum* imply reduced fitness of chloroquine-resistant parasites. *J Infect Dis* **196**:1613-1619. DOI: https://doi.org/10.1086/522154. PMID: 18008244

Phyo AP, Ashley EA, Anderson TJ, Bozdech Z, Carrara VI, Sriprawat K, Nair S, White MM, Dziekan J, Ling C, Proux S, Konghahong K, Jeeyapant A, Woodrow CJ, Imwong M, McGready R, Lwin KM, Day NPJ, White NJ, Nosten F. 2016. Declining efficacy of artemisinin combination therapy against *P. falciparum* malaria on the Thai-Myanmar border (2003-2013): The role of parasite genetic factors. *Clin Infect Dis* **63**:784-791. DOI: 10.1093/cid/ciw388. PMID: 27313266

Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, Takala-Harrison S, Witkowski B, Fairhurst RM, Aryeik, Menard D, Fidock DA. 2018. Emerging Southeast Asian PICRT mutations confer *Plasmodium falciparum* resistance to the first-line antimalarial piperquine. *Nat Commun* **9**:3314. DOI: https://doi.org/10.1038/s41467-018-05652-0. PMID: 30115924

Schmedes SE, Patel D, Dhal S, Kelley J, Svilig SS, Dimbu PR, Adeothy AL, Kahunu GM, Nkoli PM, Beavogui AH, Kariuki S, Mathanga DP, Koita O, Ichengoma D, Mohamad A, Hawela M, Moriarty LF, Samuels AM, Gutman J, Plucinski MM, Udhayakumar V, Zhou Z, Lucchi NW, Venkatesan M, Halsey ES, Talundzic E. 2021. *Plasmodium falciparum k13* Mutations, 9 Countries in Africa, 2014-2018. *Emerg Infect Dis* **27**:1902-1908. DOI: https://doi.org/10.3201/eid2707.200320. PMID: 34152946

Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, Ali F, Mohammad AB, Uhomoibhi P, Maikore I, Ogbulafor N, Nikau J, Kont MD, Challenger JD, Verity R, Lambert B, Cairns M, Rao B, Baguelin M, Whittles LK, Lees JA, Bhatia S, Knows ES, Okell L, Slater HC, Ghani AC, Walker PG, Okoko OO, Churcher TS. 2020. The potential public health consequences of COVID-19 on malaria in Africa. *Nat Med* **26**:1411-1416. DOI: https://doi.org/10.1038/s41591-020-1025-y. PMID: 32770167

Siddiqui FA, Boonhok R, Cabrera M, Mbenda HGN, Wang M, Min H, Liang X, Qin J, Zhu X, Miao J, Cao Y, Cui L. 2020. Role of *Plasmodium falciparum* K13 protein mutations in *P. falciparum* populations from northeastern Myanmar in mediating artemisinin resistance. *mBio* **11**:e01134-01119. DOI: https://doi.org/10.1128/mBio.01134-19. PMID: 32098812

Siddiqui G, Srivastava A, Russell AS, Creek DJ. 2017. Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin-resistant *Plasmodium falciparum*. *J Infect Dis* **215**:1435-1444. DOI: https://doi.org/10.1093/infdis/jix156. PMID: 28368494

Straimer J, Gnagid NF, Stokes BH, Ehrenberger M, Crane AA, Fidock DA. 2017. *Plasmodium falciparum* K13 mutations differentially impact ozonide susceptibility and parasite fitness *in vitro*. *mBio* **8**:e00172-00117. DOI: https://doi.org/10.1128/mBio.00172-17. PMID: 28400526

Straimer J, Gnagid NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD, Urnov FD, Mercereau-Pujaljor O, Benoist-Vical F, Fairhurst RM, Menard D, Fidock DA. 2015. K13-propeller mutations confer artemisinin resistance in *Plasmodium falciparum* clinical isolates. *Science* **347**:428-431. DOI: https://doi.org/10.1126/science.1260867. PMID: 25502314

Sutherland CJ, Henrici RC, Artavanis-Tsakonas K. 2020. Artemisinin susceptibility in the malaria parasite *Plasmodium falciparum*: propellers, adaptor proteins and the need for cellular healing. *FEMS Microbiol Rev* **41**:10.1093/femsre/fuaa056. PMID: 33095255

Uwimana A, LeGrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, Ngamije D, Muyaneza T, Mazarati JB, Munguti K, Campagne P, Criscuolo A, Aryeik, F, Murinahabati M, Ringwald P, Fidock DA, Mbityyumuremyi A, Menard D. 2015. Emergence and clonal expansion of *in vitro* artemisinin-resistant *Plasmodium falciparum kelch13* R561H mutant parasites in Rwanda. *Nature Med* **26**:1602-1608. DOI: https://doi.org/10.1038/s41591-020-1005-2. PMID: 32747827

Uwimana A, Umulisa N, Venkatesan M, Svilig SS, Zhou Z, Muyaneza T, Habimana RM, Rucogoza A, Moriarty LF, Sandford R, Piercefield E, Goldman I, Ezema B, Talundzic E, Pacheco MA, Escalante AA, Ngamije D, Mangala JN, Kabera M, Munguti K, Murinahabati M, Brieger W, Musanabaganwa C, Mutesa L, Udhayakumar V, Mbityyumuremyi A, Halsey ES, Lucchi NW. 2021. Association of *Plasmodium*...
Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. *Lancet Infect Dis.* DOI: [https://doi.org/10.1016/S1473-3099(21)00142-0](https://doi.org/10.1016/S1473-3099(21)00142-0). PMID: 33864801

van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, Jittamala P, Hanboonkunupakarn B, Chutasmit K, Saelow C, Runjarern R, Kaewmok W, Trijura P, Peto T, Yok S, Suon S, Sreng S, Mao S, Oun S, Yen S, Amaratunga C, Lek D, Huy R, Dhorda M, Chotivanich K, Ashley EA, Mukaka M, Wathira N, Cheah PY, Maude RJ, Amato R, Pearson RD, Goncalves S, Jacob CG, Hamilton WL, Fairhurst RM, Tarning J, Winterberg M, Kwiatkowski DP, Pukrittayakamee S, Hien TT, Day NP, Miotto O, White NJ, Dondorp AM. 2019. Determinants of dihydroartemisinin-piperaquine treatment failure in *Plasmodium falciparum* malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. *Lancet Infect Dis* 19:952-961. DOI: [https://doi.org/10.1016/S1473-3099(19)30391-3](https://doi.org/10.1016/S1473-3099(19)30391-3). PMID: 31345710

Vaughan AM, Pinapati RS, Cheeseman IH, Camargo N, Fishbaugher M, Checkley LA, Nair S, Hutrya CA, Nosten FH, Anderson TJ, Ferdig MT, Kappe SH. 2015. *Plasmodium falciparum* genetic crosses in a humanized mouse model. *Nat Methods* 12:631-633. DOI: [https://doi.org/10.1038/nmeth.3432](https://doi.org/10.1038/nmeth.3432). PMID: 26030447

White J, Dhingra SK, Deng X, El Mazouni F, Lee MCS, Afanador GA, Lawong A, Tomchick DR, Ng CL, Bath J, Rathod PK, Fidock DA, Phillips MA. 2019. Identification and mechanistic understanding of dihydroorotate dehydrogenase point mutations in *Plasmodium falciparum* that confer *in vitro* resistance to the clinical candidate DSM265. *ACS Infect Dis* 5:90-101. DOI: [https://doi.org/10.1021/acsimedic.8b00211](https://doi.org/10.1021/acsimedic.8b00211). PMID: 30375858

White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. 2014. Malaria. *Lancet* 383:723-735. DOI: [https://doi.org/10.1016/S0140-6736(13)60024-0](https://doi.org/10.1016/S0140-6736(13)60024-0). PMID: 23953767

WHO. 2019. WHO status report on artemisinin resistance and ACT efficacy. [https://www.who.int/teams/default-source/documents/publications/gmp/who-cds-gmp-2019-17-eng.pdf?ua=1](https://www.who.int/teams/default-source/documents/publications/gmp/who-cds-gmp-2019-17-eng.pdf?ua=1)

WHO. 2020. World malaria report 2020. [https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020)

Wicht KJ, Mok S, Fidock DA. 2020. Molecular mechanisms of drug resistance in *Plasmodium falciparum* malaria. *Annu Rev Microbiol.* 74:431-454. DOI: [https://doi.org/10.1146/annurev-micro-020518-115546](https://doi.org/10.1146/annurev-micro-020518-115546). PMID: 32905757

Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chour CM, Taylor WR, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D. 2013. Novel phenotypic assays for the detection of artemisinin-resistant *Plasmodium falciparum* malaria in Cambodia: *in-vitro* and *ex-vivo* drug-response studies. *Lancet Infect Dis* 13:1043-1049. DOI: [https://doi.org/10.1016/S1473-3099(13)70252-4](https://doi.org/10.1016/S1473-3099(13)70252-4). PMID: 24035558

Witkowski B, Lelièvre J, Barragan MJ, Laurent V, Su XZ, Berry A, Benoit-Vical F. 2010. Increased tolerance to artemisinin in *Plasmodium falciparum* is mediated by a quiescence mechanism. *Antimicrob Agents Chemother* 54:1872-1877. DOI: [https://doi.org/10.1128/ AAC.01636-09](https://doi.org/10.1128/ AAC.01636-09). PMID: 20160056

Witmer K, Dahalan FA, Delves MJ, Yahiya S, Watson OJ, Straschil U, Chiwcharoen D, Sornboon B, Pukrittayakamee S, Pearson RD, Howick VM, Lwaniczak MKN, White NJ, Dondorp AM, Okell LC, Chotivanich K, Ruecker A, Baum J. 2020. Transmission of artemisinin-resistant malaria parasites to mosquitoes under antimalarial drug pressure. *Antimicrob Agents Chemother* 65. DOI: [https://doi.org/10.1128/AAC.00898-20](https://doi.org/10.1128/AAC.00898-20). PMID: 33192725

Xi R, Hadjipanayis AG, Luquette LJ, Kim TM, Lee E, Zhang J, Johnson MD, Muzny DM, Wheeler DA, Gibbs RA, Kucherlapati R, Park PJ. 2011. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. *Proc Natl Acad Sci USA* 108:E1128-1136. DOI: [https://doi.org/10.1073/pnas.11110574108](https://doi.org/10.1073/pnas.11110574108). PMID: 22065754

Xiong A, Prakash P, Gao X, Chew IJ, Woodrow CJ, Engelward BP, Han J, Preiser PR. 2020. K13-mediated reduced susceptibility to artemisinin in *Plasmodium falciparum* is overlaid on a trait of enhanced DNA damage repair. *Cell Rep* 32:107996. DOI: [https://doi.org/10.1016/j.celrep.2020.107996](https://doi.org/10.1016/j.celrep.2020.107996). PMID: 32755588

Yang T, Yeoh LM, Tutor MV, Dixon MW, McMillan PJ, Xie SC, Bridgford JL, Gillett DL, Duffy MF, Ralph SA, McConville MJ, Tilley L, Cobbold SA. 2019. Decreased K13 abundance reduces hemoglobin catabolism and proteotoxic stress, underpinning artemisinin resistance. *Cell Rep* 29:2917-2928 e2915. DOI: [https://doi.org/10.1016/j.celrep.2019.10.095](https://doi.org/10.1016/j.celrep.2019.10.095). PMID: 31775055
Figure 1. Frequency and distribution of K13 alleles in 11 African countries.
Map of Africa with pie charts representing the proportions of sequenced samples per country that harbor the K13 wild-type sequence (3D7 reference), the R561H variant (the most commonly identified mutation, unique to Rwanda; see inset), or another less frequent non-synonymous K13 mutation. Sample sizes and years of sample collection are indicated. Mutations and numbers of African samples sequenced per country, and prior citations as appropriate, are listed in Figure 1–source data 1.

Figure 1–source data 1. Distribution of K13 alleles over time in African countries (2011-2019).

Figure 2. Gene-edited mutant K13 African parasites display variable levels of RSA survival.
(A-D) RSA survival rates for (A) 3D7 (Africa), (B) F32 (Tanzania), (C) UG659 (Uganda), or (D) UG815 (Uganda) K13 wild-type parental lines and CRISPR/Cas9-edited K13 R561H, M579I or C580Y mutant clones. Unedited parental lines are described in Table 1 and Supplementary file 4. For 3D7, we also included a K13 wild-type control (ctrl) line harboring silent shield mutations at the K13 gRNA cut site. Results show the percentage of early ring-stage parasites (0-3 h post invasion) that survived a 6 h pulse of 700 nM DHA, relative to DMSO-treated parasites assayed in parallel. Percent survival values are shown as means ± SEM (detailed in Figure 2–source data 1). Results were obtained from 3 to 8 independent experiments, each performed in duplicate. P values were determined by unpaired t-tests and were calculated for mutant lines relative to the isogenic line expressing wild-type K13. ** P<0.01; *** P<0.001; **** P<0.0001.

Figure 2–source data 1. Ring-stage survival (RSA) assay data for K13 edited African parasites and controls.

Figure 2–figure supplement 1. African K13 mutations result in reduced K13 protein levels in 3D7 parasites.
(A) Representative Western blot of parasite extracts probed with an anti-K13 monoclonal antibody (clone E9) that recognizes full-length K13 (~85 kDa) and lower molecular weight bands, presumably N-terminal
degradation products, as previously reported (Gnadig et al., 2020). Tightly synchronized K13 wild-type, R561H, M579I or C580Y 3D7 parasites were harvested as 0-6 h ring stages. ERD2 was used as a loading control. Experiments were performed on three independent occasions. (B) Quantification of K13 mutant protein levels versus K13 wild-type protein levels across independent replicates, performed using ImageJ, with all protein levels normalized to the ERD2 loading control. Western blots revealed reduced levels of K13 protein in the three mutant lines relative to wild-type 3D7 parasites. Results are shown as means ± SEM. WT, wild-type.

**Figure 2–figure supplement 1–source data 1.** Raw figure files for K13 Western blots performed on 3D7 parasites.

**Figure 3.** K13 mutations cause differential impacts on *in vitro* growth rates across gene-edited African strains.

(A-D) Percentage of mutant allele relative to the wild-type allele over time in (A) 3D7, (B) F32, (C) UG659, and (D) UG815 parasite cultures in which K13 mutant clones were co-cultured at 1:1 starting ratios with isogenic K13 wild-type controls over a period of 36 days. Results, shown as means ± SEM, were obtained from 2 to 5 independent experiments, each performed in duplicate. Values are provided in Figure 3–source data 1. (E) The percent reduction in growth rate per 48 h generation, termed the fitness cost, is presented as mean ± SEM for each mutant line relative to its isogenic wild-type comparator. (F) Fitness costs for mutant lines and isogenic wild-type comparators plotted relative to RSA survival values for the same lines.

**Figure 3–source data 1.** Fitness assay data for K13 edited African parasite lines and controls.

**Figure 4.** The *K13* C580Y allele has progressively outcompeted all other alleles in Cambodia.

(A-D) Stacked bar charts representing the percentage of sequenced samples expressing the *K13* wild-type allele or individual variants, calculated based on the total number of samples (listed in parentheses) for a given period. Sample collection was segregated into four regions in Cambodia (detailed in Figure 4–figure supplement 1). All K13 mutant samples harbored a single non-synonymous nucleotide polymorphism. Mutations and numbers of Cambodian samples sequenced per region/year, including prior citations as appropriate, are listed in Figure 4–source data 1.
Figure 4–source data 1. Distribution of K13 alleles over time in Cambodia (2001-2017).

Figure 4–figure supplement 1. Regions of sample collection in Cambodia for K13 sequencing. Map depicting the four regions of Cambodia (western, northern, eastern, and southern) in which samples were collected between 2001 and 2017 for K13 genotyping. Genotyping data are presented in Figure 4.

Figure 5. Southeast Asian K13 mutations yield elevated RSA survival and minor impacts on in vitro growth in gene-edited parasite lines. (A, B) RSA survival rates for Dd2 (Indochina) and Cam3.II (Cambodia) P. falciparum parasites expressing wild-type or mutant K13. Gene-edited parasites were generated using CRISPR/Cas9 or zinc-finger nucleases. Control (ctrl) lines express silent shield mutations at the K13 gRNA cut site. Parental lines are described in Table 1 and Supplementary file 4. Results show the percentage of early ring-stage parasites (0-3 h post invasion) that survived a 6 h pulse of 700 nM DHA, relative to DMSO-treated parasites processed in parallel. Percent survival values are shown as means ± SEM (detailed in Figure 5–source data 1). Results were obtained from 3 to 13 independent experiments, each performed in duplicate. P values were determined by unpaired t tests and were calculated for mutant lines relative to the isogenic line expressing wild-type K13. *** P<0.001; **** P<0.0001. (C) Percent reductions in growth rate per 48 h generation, expressed as the fitness cost, for each Dd2 mutant line relative to the Dd2WT line. Fitness costs were determined by co-culturing a Dd2eGFP reporter line with either the Dd2 K13 wild-type parental line (Dd2WT) or gene-edited K13 mutant lines. Co-cultures were maintained for 20 days and percentages of eGFP+ parasites were determined by flow cytometry (see Figure 5–source data 2 and Figure 5–figure supplement 1). Fitness costs were initially calculated relative to the Dd2eGFP reporter line (Figure 5–figure supplement 1) and then normalized to the Dd2WT line. Mean ± SEM values were obtained from three independent experiments, each performed in triplicate. (D) Fitness costs for K13 mutant lines, relative to the Dd2WT line, were plotted against their corresponding RSA survival values.
Figure 5–source data 1. Ring-stage survival (RSA) assay data for K13 edited SE Asian parasites and controls (Dd2 and Cam3.II strains).

Figure 5–source data 2. Fitness assay data (percent eGFP+ parasites) for K13 edited Dd2 parasites and parental control.

Figure 5–figure supplement 1. Southeast Asian K13 mutations result in minor in vitro growth defects in Dd2 parasites, with the exception of the C580Y and P553L mutations.

(A) Percentage of eGFP+ parasites over time in parasite cultures in which an eGFP-expressing Dd2 line was co-cultured in a 1:1 mixture with either the Dd2 K13 WT parental line (Dd2WT) or individual Dd2 gene-edited K13 mutant lines. Co-cultures were maintained over a period of 20 days, and the percentage of eGFP+ parasites in each mix was determined by flow cytometry. Data are shown as means ± SEM. Results were obtained from three independent experiments, each performed in triplicate. (B) Percent reduction in growth rate per 48 h generation, termed the fitness cost, for Dd2WT and K13-edited mutant lines relative to the Dd2eGFP line. Results are shown as means ± SEM.

Figure 6. Thai isolates expressing mutant K13 display variable RSA survival rates.

RSA survival rates for (A-E) K13-edited Thai isolates and (F) K13 E252Q unedited Thai lines, shown as means ± SEM (detailed in Figure 6–source data 1). Results were obtained from 3 to 7 independent experiments, each performed in duplicate. P values were determined by unpaired t tests and were calculated for mutant lines relative to the isogenic line expressing wild-type K13. * P<0.05; ** P<0.01; *** P<0.001.

Figure 6–source data 1. Ring-stage survival (RSA) assay data for K13 edited Thai parasites and controls.

Figure 7. Ferredoxin (fd) and multidrug resistance protein 2 (mdr2) mutations do not impact RSA survival or in vitro growth rates in K13 C580Y parasites.

RSA survival rates for (A) RF7^{C580Y} parasite lines expressing the fd variant D193Y (parent), this variant plus silent shield mutations (edited control), or fd D193 (edited revertant), and (C) Cam3.ill^{C580Y} parasite lines expressing the mdr2 variant T484I (parent), this variant plus silent shield mutations (edited control), or mdr2
T484 (edited revertant). Parental lines are described in Table 1 and Supplementary file 4. Mean ± SEM survival rates were generated from three independent experiments, each performed in duplicate. (B, D) In vitro eGFP-based fitness assays performed with (B) fd and (D) mdr2 RF7^{C580Y} or Cam3.II^{C580Y} edited lines, respectively. Competitive growth assays were seeded with individual lines plus the Dd2^{eGFP} reporter line at a 10:1 starting ratio. Results show the percentage of eGFP+ parasites over time. Co-cultures were maintained over a period of 24 days (fd-edited lines) or 30 days (mdr2-edited lines) and percentages of eGFP+ parasites were determined by flow cytometry. Results were obtained from 2-3 independent experiments, each performed in triplicate, and are shown as means ± SEM. All values are provided in Figure 7–source data 1–3.

Figure 7–source data 1. Ring-stage survival (RSA) assay data for fd and mdr2 edited parasites and controls.

Figure 7–source data 2. Fitness assay data (percent eGFP+ parasites) for RF7 fd edited parasites and parental control.

Figure 7–source data 3. Fitness assay data (percent eGFP+ parasites) for Cam3.II mdr2 edited parasites and parental control.

Figure 7–figure supplement 1. Ferredoxin (fd) and multidrug resistance protein 2 (mdr2) mutations do not impact RSA survival or in vitro growth in K13 C580Y parasites. (A, B) Ring-stage survival assays (RSAs) performed on fd and mdr2 edited lines and parental controls (RF7^{C580Y} and Cam3.II^{C580Y}, respectively). Results show RSA survival rates across a range of DHA concentrations. Survival rates were calculated relative to DMSO-treated parasites processed in parallel. Results were obtained from three independent experiments, each performed in duplicate. Data are shown as means ± SEM. (C, D) In vitro eGFP-based fitness assays performed with (C) fd and (D) mdr2 RF7^{C580Y} or Cam3.II^{C580Y} edited lines, respectively. Competitive growth assays were seeded with individual lines plus the Dd2^{eGFP} reporter line at a 100:1 starting ratio. Results show the percentage of eGFP+ parasites over time. Co-cultures were maintained over a period of 24 days (fd-edited lines) or 30 days (mdr2-edited lines) and percentages of eGFP+ parasites...
were determined by flow cytometry. Results were obtained from 2 to 3 independent experiments, each performed in triplicate, and are shown as means ± SEM.

**Supplementary Files**

**Supplementary file 1. Sample information and approval from within-country ethics committees for K13 genotyping data.**

**Supplementary file 2. CRISPR/Cas9 strategy for editing the K13 locus.**

All-in-one plasmid approach used for CRISPR/Cas9-mediated K13 gene editing, consisting of a K13-specific donor template for homology-directed repair, a K13-specific gRNA expressed from the U6 promoter, a Cas9 cassette with expression driven by the calmodulin (cam) promoter, and a selectable marker (human dhfr, conferring resistance to the antimalarial WR99210 that inhibits *P. falciparum* dhfr). The Cas9 sequence was codon-optimized for improved expression in *P. falciparum*. Donors coding for specific mutations of interest (e.g., K13 C580Y, red star) were generated by site-directed mutagenesis of the K13 wild-type donor sequence. Green bars indicate the presence of silent shield mutations that were introduced to protect the edited locus from further cleavage. The lightning bolt indicates the location of the cut site in the genomic target locus. Primers used for cloning and final plasmids are described in Supplementary files 7 and 8, respectively.

**Supplementary file 3. Crystal structure of K13 propeller domain showing positions of mutated residues.**

(A, B) Top and (C, D) side views of the crystal structure of the K13 propeller domain (PDB ID: 4YY8), highlighting residues of interest (F446I, orange; R539T, dark blue; I543T, purple; P553L, pink; R561H, dark turquoise; P574L, light turquoise; M579I medium blue; C580Y, red). Structures shown in (A) and (C) show wild-type residues while (B) and (D) show mutated residues.

**Supplementary file 4. Geographic origin and drug resistance genotypes of *Plasmodium falciparum* clinical isolates and reference lines employed in this study.**
Supplementary file 5. Transgenic *Plasmodium falciparum* lines generated in this study.

Supplementary file 6. CRISPR/Cas9 strategy for editing the *ferredoxin (fd)* and *multidrug resistance protein 2 (mdr2)* loci.

All-in-one plasmid approaches used for CRISPR/Cas9-mediated editing of (A) the *ferredoxin (fd)* locus or (B) the *multidrug resistance protein 2 (mdr2)* locus. Plasmids consisted of a *fd* (A) or *mdr2* (B) specific donor template for homology-directed repair, a gene-specific gRNA expressed from the *U6* promoter, a Cas9 cassette with expression driven by the *cam* promoter, and a selectable marker (human *dhfr*, conferring resistance to WR99210). Donors coding for specific mutations of interest (*fd D193Y* or *mdr2 T484I*) were generated by site-directed mutagenesis of the wild-type donor sequences. Red bars indicate the presence of silent shield mutations used to protect edited loci from further cleavage. Primers used for cloning and final plasmids are described in Supplementary files 7 and 8, respectively.

Supplementary file 7. Oligonucleotides used in this study.

Supplementary file 8. Description of gene-editing plasmids generated in this study.

Supplementary file 9. Real-Time PCR (qPCR) primers and probes used in this study.
| Parasite | Origin     | Year  | K13 | Resistance |
|----------|------------|-------|-----|------------|
| 3D7<sup>WT</sup> | Africa     | 1981  | WT  | --         |
| F32<sup>WT</sup> | Tanzania   | 1982  | WT  | --         |
| UG659<sup>WT</sup> | Uganda     | 2007  | WT  | CQ, SP     |
| UG815<sup>WT</sup> | Uganda     | 2008  | WT  | CQ, SP     |
| Dd2<sup>WT</sup> | Indochina  | 1980  | WT  | CQ, MFQ, SP|
| Cam3.II<sup>WT</sup> | Cambodia   | 2010  | WT  | CQ, SP     |
| CamWT<sup>C580Y</sup> | Cambodia   | 2010  | C580Y | ART, CQ, SP|
| RF7<sup>C580Y</sup> | Cambodia   | 2012  | C580Y | ART, CQ, PPQ, SP|
| Thai1<sup>WT</sup> | Thailand   | 2003  | WT  | CQ, SP     |
| Thai2<sup>WT</sup> | Thailand   | 2004  | WT  | CQ, MFQ, SP|
| Thai3<sup>WT</sup> | Thailand   | 2003  | WT  | CQ, SP     |
| Thai4<sup>WT</sup> | Thailand   | 2003  | WT  | CQ, SP     |
| Thai5<sup>WT</sup> | Thailand   | 2011  | WT  | CQ, SP     |
| Thai6<sup>E252Q</sup> | Thailand   | 2008  | E252Q | ART (low), CQ, MFQ, SP|
| Thai7<sup>E252Q</sup> | Thailand   | 2010  | E252Q | ART (low), CQ, MFQ, SP|

ART, artemisinin; CQ, chloroquine; MFQ, mefloquine; PPQ, piperaquine; SP, sulfadoxine/pyrimethamine; WT, wild type.
Table 1

| Country                  | Sample Period      | Total Samples |
|--------------------------|--------------------|---------------|
| Rwanda                   | (2012-2015)        | 927           |
| Chad                     | (2015)             | 389           |
| Burundi                  | (2015-2016, 2019)  | 187           |
| Rep. of the Congo        | (2014-2015, 2017-2019) | 98            |
| Central African Rep.     | (2017-2019)        | 187           |
| Equatorial Guinea        | (2014)             | 98            |
| Somalia                  | (2016-2017)        | 138           |
| Somaliland               | (2016-2017)        | 138           |
| The Gambia               | (2014-2016)        | 313           |
| Sierra Leone             | (2016)             | 278           |
| Burkina Faso             | (2017-2018)        | 367           |
| Burundi                  | (2015-2016, 2019)  | 193           |
| Tanzania                 | (2011-2012, 2015)  | 389           |
| Rep. of the Congo        | (2015-2016, 2017-2019) | 313           |
| Total%                   |                    |               |
| Total%                   |                    | 100           |

**Figure 1**

The map illustrates the distribution of K13 wild-type, K13 R561H, and K13 mutant (other) across various African countries. The bar graph on the right shows the percentage of total samples for each category.
Figure 2

(A) 3D7

WT ctrl

R561H M579I C580Y

RSA survival rate (%)

0.1 1 10 100

WT M579I C580Y

(B) F32

RSA survival rate (%)

0.1 1 10 100

WT R561H M579I C580Y

(C) UG659

RSA survival rate (%)

0.1 1 10 100

WT M579I C580Y

(D) UG815

RSA survival rate (%)

0.1 1 10 100

WT M579I clone 1 M579I clone 2 C580Y

**** **** ****
Figure 3

(A) 3D7

(B) F32

(C) UG659

(D) UG815

(E) Fitness cost (%) per generation (relative to isogenic WT parent)

(F) RSA survival rate (%)
**Figure 4**

(A) Western Cambodia

(B) Northern Cambodia

(C) Eastern Cambodia

(D) Southern Cambodia
Figure 5

A. RSA survival rate (%) for WT ctrl and various mutants of Dd2.

B. RSA survival rate (%) for WT ctrl and various mutants of Cam3.II.

C. Fitness cost (%) per generation for Dd2 mutants relative to Dd2 WT.

D. Fitness cost (%) per generation for Dd2 mutants relative to Dd2 WT.
Figure 7

A

RSA survival rate (%)

RF7 fd D193Y
RF7 fd D193Y ctrl
RF7 fd D193 rev

B

Day

Percent eGFP+

RF7<sup>C580Y</sup> fd rev
RF7<sup>fd D193Y</sup> ctrl
RF7<sup>fd D193</sup>

C

RSA survival rate (%)

Cam3.II<sup>mdr2 T484I</sup> rev
Cam3.II<sup>mdr2 T484I</sup> ctrl
Cam3.II<sup>mdr2 T484</sup> rev

D

Day

Percent eGFP+

Cam3.II<sup>mdr2 T484I</sup> rev
Cam3.II<sup>mdr2 T484I</sup> ctrl
Cam3.II<sup>mdr2 T484I</sup>
Figure 2–figure supplement 1

A

kDa
100
75
50
20

α-K13 (mAb)

B

K13/ERD2

3D7WT
3D7R561H
3D7M579I
3D7C580Y

α-ERD2 (loading control)
Figure 5–figure supplement 1

A

Day

Percent eGFP+

0 2 4 6 8 10 12 14 16 18 20

B

Fitness cost (%) per generation

(relative to Dd2<sup>eGFP</sup>)

Dd2<sup>WT</sup>

Dd2<sup>ctrl</sup>

Dd2<sup>E252Q</sup>

Dd2<sup>F446I</sup>

Dd2<sup>P553L</sup>

Dd2<sup>R561H</sup>

Dd2<sup>P574L</sup>

Dd2<sup>C580Y</sup>
Figure 7—figure supplement 1

**A**

% Survival vs [DHA] (nM)

- RF7<sup>fd</sup> D193Y
- RF7<sup>fd</sup> D193Y ctrl
- RF7<sup>fd</sup> D193 rev

**B**

% Survival vs [DHA] (nM)

- Cam3.II<sup>mdr2 T484I</sup>
- Cam3.II<sup>mdr2 T484I</sup> ctrl
- Cam3.II<sup>mdr2 T484 rev</sup>

**C**

Percent eGFP+ vs Day

- RF7<sup>fd</sup> D193Y
- RF7<sup>fd</sup> D193Y ctrl
- RF7<sup>fd</sup> D193 rev

**D**

Percent eGFP+ vs Day

- Cam3.II<sup>mdr2 T484I</sup>
- Cam3.II<sup>mdr2 T484I</sup> ctrl
- Cam3.II<sup>mdr2 T484 rev</sup>